Next Article in Journal
Integrative Proteomics Reveal Neuroimmune and Dopaminergic Alterations Across the Nociceptive Neuraxis in Neuropathic Pain
Previous Article in Journal
FRY Mediates THP1-Driven Ovarian Cancer Invasion Through the PI3K/AKT Pathway
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cells
Volume 15
Issue 3
10.3390/cells15030288
cells-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Copper, Ceruloplasmin, Zinc, and Manganese Levels in Brain and Biological Fluids from Parkinson’s Disease Patients: Systematic Review and Meta-Analysis

by
Félix Javier Jiménez-Jiménez
1,*,
Hortensia Alonso-Navarro
1,
Elena García-Martín
2,
Miguel Angel Martín-Gómez
1,
Paula Salgado-Cámara
1,
Alba Cárcamo-Fonfría
1,
Margarita Arroyo-Solera
1 and
José A. G. Agúndez
2,*
1
Section of Neurology, Hospital Universitario del Sureste, Ronda del Sur 10, 28500 Arganda del Rey, Madrid, Spain
2
University Institute of Molecular Pathology Biomarkers, Universidad de Extremadura, 10071 Cáceres, Spain
*
Authors to whom correspondence should be addressed.
Cells 2026, 15(3), 288; https://doi.org/10.3390/cells15030288
Submission received: 19 December 2025 / Revised: 23 January 2026 / Accepted: 29 January 2026 / Published: 3 February 2026
Browse Figures
Review Reports Versions Notes

Abstract

The present systematic review and meta-analysis aims to establish whether the brain, cerebrospinal fluid (CSF), serum/plasma whole blood, urine, and hair levels of copper, ceruloplasmin, zinc, and manganese are related to the risk for Parkinson’s disease (PD). We reviewed the PubMed and Web of Science Core Collection databases from 1966 to 29 November 2025, and identified references of interest for this topic. We performed the meta-analysis of eligible studies that followed the PRISMA and MOOSE guidelines, with the R software package meta R 4.2.0 version. When compared to age- and sex-matched controls, PD patients showed decreased concentrations of copper in the substantia nigra and other brain areas, a trend towards increased CSF and decreased serum/plasma copper levels, decreased serum/plasma ceruloplasmin levels, decreased zinc levels in serum/plasma and increased zinc in whole blood and hair, and increased hair manganese levels. These results suggest an association between these transition metals and risk for PD.

1. Introduction

The main neuropathological features of Parkinson’s disease (PD)—the neurodegeneration of the dopaminergic neurons at the substantia nigra compacta—and the presence of Lewy bodies (composed of alpha-synuclein aggregates), are well established. However, its etiology and the pathogenetic mechanisms leading to the neurodegenerative processes are not well-known. The interplay of genetic and environmental factors could hypothetically induce a dysregulation of multiple cellular pathways, including oxidative stress, mitochondrial dysfunction, neuroinflammation, trophic factor deficiency, excitotoxicity, alterations in the mechanisms implicated in protein clearance, intracellular calcium accumulation, synaptic dysfunction, etc., that would eventually result in neuronal and glial cell death [1,2]. Many reports published in the last decade have suggested that oxidative stress (defined as the imbalance between the production of free radicals and diverse mechanisms against oxidative processes)—with the involvement of transition metals such as copper, zinc, manganese, and iron—plays an important role in the pathogenesis of PD [3,4,5,6].
A meta-analysis of brain copper and zinc concentrations in post-mortem tissue showed decreased copper and similar zinc levels in the substantia nigra of PD patients compared to controls [7]. Another meta-analysis, including only works published between 2011 and 2022, reported “lower copper content in postmortem brain tissue”, by mixing the copper concentrations found in different tissues from different studies [8]. However, findings from meta-analyses assessing copper, zinc, and manganese concentrations in cerebrospinal fluid (CSF), serum, plasma, and urine of patients with PD compared to controls have been inconsistent. Two studies reported no significant differences in CSF, serum, or plasma levels of zinc, copper, and manganese [3,7]. Similarly, Adani et al. [9] found no significant differences in CSF and serum/plasma copper levels, as well as in CSF zinc levels. In contrast, other authors described an association between reduced serum/plasma zinc concentrations and increased PD risk [9,10,11]. They also reported a trend toward lower serum copper concentrations in PD patients compared to controls [8].
In the current meta-analysis, we analyzed the results of studies on the concentrations of copper, ceruloplasmin, zinc, and manganese in different brain regions, in the CSF, in serum/plasma, urine, and hair of PD patients compared to controls. For this purpose, we analyzed the pooled results of studies giving data on the absolute concentrations of these variables.

2. Methods

2.1. Search Strategy

We performed a complete literature search, without any language restrictions, using two Databases (PubMed and the Core Collection of Web of Science) up to 29 November 2025. The search strategy used the term “Parkinson’s Disease” that was crossed with combinations of the terms “brain”, “cerebrospinal fluid”, “serum”, “plasma”, “blood”, “urine”, “hair”, “copper”, “ceruloplasmin”, “zinc”, and “manganese”. Table 1 summarizes the number of references obtained for each combination. The whole search retrieved a total of 2023 items.

2.2. Criteria for Eligibility and Exclusion of Studies from the Meta-Analyses

We screened the abstracts of all original articles; publications in abstract form were excluded from further analysis. The initial selection included 85 studies measuring brain, CSF, serum/plasma, urine, and/or hair concentrations of copper, ceruloplasmin, zinc, or manganese [12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98]. The authors, year of publication, methods used to perform the determinations, and observations (including the reasons for exclusion from the meta-analysis) when appropriate, were summarized in Table 2.
Some articles were excluded, totally or partially, from the meta-analyses because of the following reasons: (A) total or partial overlapping with other articles from the same group [31,51,52,53,75,78]; (B) lack of a control group [55,64,74,75,88,94]; (C) lack of part of the data in the text, tables or figures [21,58,60,89,91,92,96]; (D) measurements given in units different from those used in most articles without the possibility of conversion [16,32,49,80], and (E) inability to obtain the original article [22]. The flowchart for the selection of the studies is plotted in Figure 1.
Selected case–control studies reporting brain, CSF, serum/plasma, urine, and hair concentrations of copper, ceruloplasmin, zinc, and manganese are summarized in Supplementary Table S1. The results of all studies were given as mean ± SD values. All concentrations were standardized to the same units across studies, converting values when necessary. The odds ratios (OR) and 95% confidence intervals (95% CI), and the statistical significance of each individual study, were calculated.

2.3. Statistical Analysis

Meta-analyses were carried out using the R software package meta R 4.2.0 version. [99] and followed by the PRISMA [100] (Supplementary Table S2) and MOOSE guidelines [101] (Supplementary Table S3), to maintain methodological transparency, accuracy, and reproducibility. The review protocol was not registered in PROSPERO due to the rapid timeline of the project and because the scope of the study, which involved synthesizing previously published datasets, did not involve patient-level intervention or outcomes requiring prospective pre-registration. Because of the observed high heterogeneity across studies, we used the random-effects model to calculate the p values, although the plots also included the common effects models for comparison. The meta-analytical procedure used was the inverse variance method, with DerSimonian-Laird estimator for Tau2, Jackson method for the confidence interval of Tau2 and Tau, and Hedges’ g (bias-corrected standardized mean difference). We calculated the statistical power to detect differences in mean values (alpha = 0.05) for the pooled samples when stated in the text.

3. Results

3.1. Copper

3.1.1. Brain

The results of studies assessing copper concentrations in different brain regions are summarized in Table 2 and Supplementary Table S1. In the meta-analysis, we only included those studies in which copper concentrations were expressed in μg/g tissue or could be converted to this unit. A total of five studies measuring copper levels in the substantia nigra (total), involving 70 PD patients and 94 controls [13,14,15,17,19], showed a significant decrease in PD patients (Figure 2a). Loeffler et al. [16] also reported decreased copper concentrations in the substantia nigra of PD patients expressed as ng/μg of protein [16], and Genoud et al. [21] reported a 54% decrease in copper in the substantia nigra of PD patients, but full data were not available. In contrast, another two studies showed similar copper concentrations between PD patients and controls assessed by ceruloplasmin staining [80] and synchrotron radiation-based X-ray fluorescence [18]. Dexter et al. [13] reported decreased copper levels in the substantia nigra pars compacta from PD patients, and Riederer et al. [12] did not find significant differences in the copper concentrations in the pars oralis or in the pars caudalis of the substantia nigra between PD patients and controls.
The pooled data of four studies, involving 62 PD patients and 82 controls [12,13,14,15], showed a significant decrease in copper concentrations in the caudate of PD patients (Figure 2b). Another study showed decreased caudate copper levels in PD patients expressed as ng/μg of protein [16], and another did not find significant differences between PD patients and controls measured as ceruloplasmin staining [80].
Copper concentrations in total putamen are decreased in PD patients compared to controls in pooled data from three studies [12,13,15] involving 39 PD patients and 59 controls (Figure 2c). In one of these studies, the concentrations of copper in medial and in lateral putamens did not, however, show significant differences between study groups [13]. Copper levels were also found to decrease in PD patients at globus pallidus medialis [13,15], globus pallidus lateralis [13,15], and cerebellum [13,14,15] (Figure 2d, Figure 2e and Figure 2f, respectively), whereas copper levels were similar in PD patients and controls in the cerebral cortex [13,15] (Figure 2g). Finally, some individual studies showed decreased copper concentrations in the raphe plus reticular formation [12], red nucleus [12], locus ceruleus [19], olfactory bulb [20], and amygdala [12], and increased copper levels in the CA1 area [80] (Table 2 and Supplementary Table S1).

3.1.2. Cerebrospinal Fluid

Sixteen studies addressed CSF copper levels, but two of them were excluded from the meta-analysis because of the previously mentioned reasons (Table 2 and Supplementary Table S1) [22,32]. One of them found CSF copper concentrations decreased [29], four were increased [24,33,36,37], and nine were similar in PD patients compared to controls [23,25,26,27,28,30,31,34,35]. The final meta-analysis, which involved 564 PD patients and 429 controls, showed a non-significant increase in PD patients according to the random effects model, although the common effect model indicates that the difference is significant (p = 0.0021) (Figure 3a).

3.1.3. Serum/Plasma

Forty-two studies addressed serum (32 studies) or plasma (10 studies) copper concentrations (Table 2 and Supplementary Table S1); it was significantly increased in PD patients in seven studies [31,39,43,44,57,59,63], decreased in fourteen studies [28,30,45,48,49,61,62,66,67,68,69,71,72,73], and similar to those of controls in seventeen studies [23,26,29,34,38,40,41,42,46,47,50,51,52,54,59,70,76]. Four studies [55,64,74,75] showed results of PD patients but lacked control groups. The final meta-analysis involved 2894 PD patients and 2549 controls, and showed a slight, non-significant decrease in serum/plasma copper concentrations in PD patients compared to controls according to the random effects model, although the common effect model indicates that the difference is significant (p < 0.0001) (Figure 3b).

3.1.4. Whole Blood

Bocca et al. [30] showed increased concentrations of copper in the whole blood of PD patients, while another two studies showed similar levels between PD patients and controls (Table 2 and Supplementary Table S1) [37,59]. The pooled data from these three studies (216 PD patients and 169 controls) showed a non-significant increase in copper concentrations in PD patients (Figure 3c).

3.1.5. Urine

Copper concentrations were found to be increased in the urine in PD patients in one study [50,51,52], decreased in two [30,70], and similar to those of controls in another three studies (Table 2 and Supplementary Table S1) [28,59,77]. The pooled data of these studies, involving 331 PD patients and 313 controls, showed non-significant differences between PD patients and controls (Figure 3d).

3.1.6. Hair

Ajsuvakova et al. [70] found decreased concentrations of copper in the hair of PD patients, while other authors did not find significant differences between PD patients and controls (Table 2 and Supplementary Table S1) [30,78,79]. The meta-analysis, which involved 140 PD patients and 55 controls, did not show significant differences (Figure 3e).

3.2. Ceruloplasmin

3.2.1. Brain

Loeffler et al. [16] reported increased concentrations of copper in the caudate, putamen, substantia nigra, hippocampus, temporal, frontal, and parietal cortex, and cerebellum from PD patients compared to controls (Table 2 and Supplementary Table S1). Data from this study have not been replicated to date.

3.2.2. Cerebrospinal Fluid

Only two studies with a small sample size analyzed CSF ceruloplasmin levels in PD and controls, one of them showing these values as increased in PD [81] and the other indicating non-significant differences [23] (Table 2 and Supplementary Table S1). The pooled data (31 PD patients and 14 controls) showed non-significant differences between PD patients and controls.

3.2.3. Serum/Plasma

Ceruloplasmin levels were assessed in serum by sixteen studies and in plasma by another three studies (Table 2 and Supplementary Table S1). Six studies showed decreased serum/plasma ceruloplasmin levels in PD patients [48,65,67,68,84,85], while another twelve did not show significant differences [33,40,42,46,54,58,66,73,82,83,86,87]. Another study [88] was not included in the meta-analysis because it lacked a control group. The pooled data (1079 PD patients and 904 controls) showed a significant decrease in serum/plasma ceruloplasmin levels in PD patients as compared to controls (Figure 4).

3.3. Zinc

3.3.1. Brain

Table 2 and Supplementary Table S1 summarize the results of studies assessing concentrations of zinc in different brain regions. The meta-analysis included only those studies in which zinc concentrations were expressed in μg/g tissue or could be converted to this unit. Four studies involving 53 PD patients and 65 controls [13,14,15,19] measuring zinc levels in the substantia nigra (total) showed non-significant differences between PD patients and controls (Figure 5a). Mann et al. [90] showed non-significant differences in zinc concentrations in the substantia nigra in the two study groups expressed as ng/μg of protein. Dexter et al. [13] reported similar zinc levels in the substantia nigra pars compacta from PD patients and controls, and, similarly, Riederer et al. [12] did not find significant differences in the copper concentrations in either the pars oralis or the pars caudalis of the substantia nigra.
Concentrations of zinc in caudate nuclei (Figure 5b) [12,13,14,15], putamen (Figure 5c) [12,13,15], and globus pallidus medialis (Figure 5d) [13,15] were similar in PD patients and controls. In the globus pallidus lateralis, there was a significant increase in PD patients with the use of the common effects model (p = 0.0088), but not with the random effects model (Figure 5e) [13,15]; in the cerebral cortex (Figure 5f) [13,15] they were similar in PD patients and controls. Cerebellum zinc levels were increased in PD patients, although this finding was not significant using the random effects model, the common effects models indicated a p value < 0.001 (Figure 5g) [13,14,15]. Some individual studies described non-significant differences in zinc levels between PD patients and controls in putamen medial [13], putamen lateral [13], globus pallidus total [12], frontal cortex [14], occipital cortex [19], amygdala [12], cingulate gyrus [12], raphe plus reticular formation [12], red nucleus [12], and ceruleus [19], olfactory bulb [20], and olfactory tract [20].

3.3.2. Cerebrospinal Fluid

CSF zinc levels were addressed in ten studies (Table 2 and Supplementary Table S1), being significantly decreased in PD patients in four of them [26,29,34,37], increased in two [33,36], and similar to those of controls in another four [28,30,31,35]. The pooled results, involving 473 PD patients and 454 controls, showed a non-significant trend towards increased CSF zinc concentrations in PD patients, although the differences were significant in the common effects model (p = 0.0034) (Figure 6a).

3.3.3. Serum/Plasma

Thirty-four studies addressed serum (twenty-eight studies) or plasma (four studies) zinc concentrations (Table 2 and Supplementary Table S1). Eleven of them reported decreased zinc levels in PD patients [29,31,41,44,49,57,62,71,72,76,93], and eighteen did not find significant differences between PD patients and controls [26,28,30,34,40,43,46,47,50,51,52,53,56,59,61,69,70,92]. Four studies did not include a control group [64,74,75,94] and therefore were not included in the meta-analysis. The final meta-analysis, which included 2476 PD patients and 2018 controls, showed a significant decrease in serum/plasma zinc levels in PD patients (Figure 6b).

3.3.4. Whole Blood

Two studies showed increased concentrations of zinc in whole blood from PD patients compared to controls [30,37], and another did not find significant differences (Table 2 and Supplementary Table S1) [59]. The pooled data showed a significant trend towards increased zinc concentrations in whole blood from PD (Figure 6c).

3.3.5. Urine

Six studies addressed urine zinc levels. Only one of these studies showed a significant decrease in PD patients [70], and the others did not show significant differences between PD patients and controls (Table 2 and Supplementary Table S1) [20,28,51,52,53,59,77]. The results of the meta-analysis showed a non-significant decrease in PD patients (Figure 6d).

3.3.6. Hair

The pooled data of four studies addressing hair zinc levels did show a significant increase in this value in PD patients (Table 2 and Supplementary Table S1, Figure 6e).

3.4. Manganese

3.4.1. Brain

Two individual studies did not show significant differences between PD patients and controls in the concentration of manganese in several brain areas, including the frontal cortex [14], caudate [14], substantia nigra [14], cerebellum [14], olfactory bulb [20], and olfactory tract [20] (Table 2 and Supplementary Table S1).

3.4.2. Cerebrospinal Fluid

CSF manganese levels were addressed by ten studies (Table 2 and Supplementary Table S1), four of them showing decreased CSF Mn in PD patients [30,31,32,33,34,37] and others showing non-significant differences when compared to controls [24,25,26,28,35,36,37]. The analysis of pooled data did not show significant differences between PD patients and controls in the random effects models, although it did in the common effects model (p = 0.0013) (Figure 7a).

3.4.3. Serum/Plasma

Thirteen studies assessed serum and one analyzed the plasma levels of Mn in PD patients; two of the studies lacked a control group (Table 2 and Supplementary Table S1). The meta-analysis of eligible studies, including 1154 PD patients and 994 controls, showed a non-significant increase in serum/plasma manganese in PD patients, which was marginally significant in the common effects model (p = 0.0333) (Figure 7b).

3.4.4. Whole Blood

Whole blood manganese levels were addressed by two groups [30,50,51,52,53] (Table 2 and Supplementary Table S1), which were higher in PD patients than in controls (Figure 7c).

3.4.5. Urine

Urine manganese levels were researched in six studies involving 337 PD patients and 316 controls. One of these studies showed a significant decrease [30] and another a significant increase in PD patients [77], but the results of the meta-analysis showed non-significant differences between PD patients and controls (Figure 7d).

3.4.6. Hair

Two of the three studies addressing hair manganese levels [30,79], and the pooled data from these studies, involving 150 PD patients and 56 controls (Table 2 and Supplementary Table S1, Figure 7e), showed a significant increase in PD patients.

4. Discussion

Together with iron, other transition metals such as copper, zinc, and manganese seem to play a role in the generation of free radicals and oxidative stress contributing to the neuronal degeneration in the substantia nigra pars compacta in the PD brain. In this review and meta-analysis, we have tried to establish the status of these transition metals and ceruloplasmin (the main copper-related protein) in patients with PD.
Copper plays several biological roles, including its involvement in iron homeostasis and its function as a cofactor for numerous metalloproteins and metalloenzymes, such as ceruloplasmin, Cu/Zn superoxide-dismutase, cytochrome c oxidase, and dopamine beta hydroxylase. In addition, it intervenes in the biosynthesis of neurotransmitters and peptide hormones, and in the protection against free radicals [102]. In the current meta-analysis, we have shown a significant decrease in copper concentrations in the substantia nigra, caudate nuclei, putamen, globus pallidus medialis and lateralis, and cerebellum of patients with PD compared to controls. It is likely that copper levels were also decreased in other brain areas, according to the results of some individual studies, but these data would need to be replicated. We have also found a non-significant trend towards increased levels of copper in CSF and towards decreased copper levels in serum/plasma (according to the random effects model, which is more reliable than the common effect model, although according to which these changes were significant), as well as increased copper levels in the whole blood of patients with PD compared to controls, while copper levels in urine and hair did not differ significantly between the two study groups.
Reduced copper levels in the substantia nigra should hypothetically result in an impairment of defences against oxidative processes, leading to increased oxidative stress, mitochondrial dysfunction and increased neuronal vulnerability. Copper deficiency seems to alter the expression of key proteins in iron metabolism and is associated with dysfunction in iron export and iron accumulation [103]; increased iron in the substantia nigra is a well demonstrated feature in PD. In addition, it has been shown that copper is able to bind α-synuclein with high affinity, consequently promoting its aggregation, and this binding would lead to a decrease in copper concentration [104,105]. Interestingly, it has been shown that significant amounts of Fe, Cu and Zn are bound to neuromelanin in the neurons of human putamen, premotor cortex, cerebellum, and substantia nigra in normal subjects [106], and vulnerability of the dopaminergic neurons in the substantia nigra seems to be related to their neuromelanin content [107]. Substantia nigra and locus coeruleus (the regions that have the highest neuronal loss in PD), that contain a high amount of neuromelanin bound to these metals, show age-related changes in copper and zinc concentrations (especially a decrease in copper concentrations in locus coeruleus) [108].
In agreement with our study, a previous meta-analysis showed decreased copper concentrations in the substantia nigra of PD patients, but in this study, the authors did not analyze copper concentrations in other brain areas [7]. Scolari-Grotto et al. [8], in a meta-analysis that only included articles published between 2011 and 2022 (therefore excluding several important pioneer studies), reported “decreased brain copper levels”, but in such a study, the authors combined the concentrations of copper in several brain areas. Two previous meta-analyses, with a lower number of studies analyzed and a lower sample size than the current meta-analysis, did not find significant differences in CSF copper levels between PD patients and controls [3,7,9]. These studies also described a non-significant trend towards lower serum/plasma copper levels in PD patients [3,7,9], similar to the results obtained by the random effects model in the current study. Scolari-Grotto et al. [8], with a lower sample size, also described decreased serum/plasma copper in PD patients. To our knowledge, concentrations of copper in whole blood (increased in this study), urine (similar to those of controls), and hair (similar to those of controls) in PD patients have not been addressed previously in other meta-analyses.
The ferroxidase enzyme ceruloplasmin, which is the main copper-carrying protein in the blood, and which plays an important role in iron metabolism, has also been found to be significantly decreased in the serum/plasma from PD patients compared to controls in the current study. This result is in disagreement with that of Wei et al. [3], who, in a meta-analysis with a considerably smaller sample size, did not find significant differences between patients with PD and controls. Data from studies on the brain [16] and CSF [23,81] are insufficient to draw valid conclusions. Ceruloplasmin, acting as ferroxidase, converts Fe2+ to less toxic Fe3+, and it has been shown that low ceruloplasmin concentration and activity in serum seems to be correlated to the high iron amounts in the substantia nigra [109].
Biological functions of zinc include, among many others, direct or indirect antioxidant actions, acting as a cofactor of Cu/Zn superoxide-dismutase, intervening in the synthesis of metallothioneins and metalloproteins/metalloenzymes, increasing glutathione peroxidase activity, regulation of apoptosis and inflammatory processes, participation in protein, RNA and DNA synthesis and in DNA replication, and being a cofactor of many enzymatic reactions and transcription factors [102]. The current meta-analysis showed increased zinc levels in the cerebellum and globus pallidus lateralis of PD patients with the common effect models (which was not confirmed with the more reliable random effect models), with non-significant differences between PD patients and controls in other brain regions, including the substantia nigra (in agreement with Genoud et al. [7]), caudate, and putamen. In agreement with previous meta-analyses [3,7,9], our results did not find significant differences in CSF levels between PD patients and controls, although there was a trend towards increased CSF levels in PD patients. Serum/plasma zinc concentrations were significantly lower in PD patients, as previously reported by other meta-analytic studies with smaller sample sizes [3,7,9,10,11]. In addition, we have shown, apparently for the first time, increased whole blood and hair zinc levels in PD patients and similar urine zinc levels in PD patients and controls. Lower systemic (serum/plasma) zinc and increased zinc levels in blood cells and hair in PD patients could reflect redistribution to tissues or altered zinc homeostasis [110], but decreased serum/plasma zinc levels could be a consequence of oxidative stress processes as well [26]. In addition. it has been shown that the binding of zinc to α-synuclein promotes its aggregation toward accelerated amyloid formation [111], a mechanism that could be involved in the formation of structures similar to Lewy bodies—the hallmark of PD.
Manganese acts as a cofactor of many metalloproteins/metalloenzymes—such as Mn-superoxide dismutase (oxidative stress), phosphoenolpyruvate carboxykinase (gluconeogenesis), pyruvate carboxylase (gluconeogenesis and lipogenesis), acetyl-CoA decarboxylase (fatty acid synthesis), glutamine synthetase (metabolism of glutamate to glutamine)—plays an important role in the homeostasis of iron, copper, zinc, and calcium, and has effects on several neurotransmitter systems, including dopaminergic (reduced dopamine levels by reduction in tyrosine hydroxylase activity), GABAergic, glutamatergic, and cholinergic [102]. Data from studies on the brain [14,20] were scarce and did not lead to valid conclusions. According to the current meta-analysis, CSF, serum/plasma, whole blood and urine manganese concentrations were similar in PD patients and controls, and were significantly increased in the hair of PD patients. Our results regarding CSF manganese levels were in agreement with those of previous meta-analyses with smaller sample sizes [3,7,112]. Similarly to our study, the other two meta-analyses did not find significant differences between PD patients and controls in serum/plasma manganese levels [3,7], while another one described this parameter as increased in PD patients [112]. To our knowledge, our meta-analysis is the first addressing urine and hair manganese concentrations in PD. Increased manganese in hair could be related to systemic manganese imbalance in PD patients, possibly reflecting altered manganese metabolism or excretion.
To date, there are only a few studies on the levels of copper, ceruloplasmin, zinc, and manganese in experimental models of PD. Interestingly, in the model of PD induced by 6-hydroxydopamine in rats, the concentrations of copper, zinc, and manganese in the substantia nigra, globus pallidus, putamen, and amygdala increased after injection of this toxin in the medial forebrain bundle [113], while mRNA and protein expressions of CP in the substantia nigra decreased compared to controls [114]. Administration of 1-methyl-4-phenyl-tetrahydropyridine (MPTP) to rodents caused an increase in copper concentrations in the rostral periventricular zone and a mild decrease in the interpeduncular nucleus, but no changes in the substantia nigra [115]. Finally, administration of the copper chelator D-penicillamine was not able to prevent MPTP-induced dopamine depletion in mice [116].
The main strength of our study would be the significant sample size, especially concerning studies conducted in serum/plasma and CSF, which would have considerable statistical power. However, as the main limitation, there was substantial variability among the different studies included, likely related both to methodological aspects and to the selection criteria used for patients with PD, which led to considerable heterogeneity in the pooled results. Table 3 summarizes the main advantages, limitations, and sensitivity of the different methods used for the determination of copper, zinc, and manganese levels in the studies included in the meta-analyses [117,118,119,120,121,122,123]. In any case, the exclusion of studies without a control group ensures that, for each of the studies included in the meta-analysis, the experimental conditions for patients with PD and the controls are the same. In addition, to exclude a possible influence of studies with data collected close to 1966, we performed a subgroup analysis including only those studies published after 1985 which showed the same results.

5. Conclusions

Taking these limitations into account, the main findings of this meta-analysis were (1) the decrease in copper concentrations in many brain regions, including the substantia nigra and basal ganglia; (2) the decrease in ceruloplasmin levels in the serum/plasma of PD patients; (3) the decrease in serum/plasma and increase in whole blood and hair zinc concentrations in PD patients; and (4) the increase of manganese levels in the hair of PD patients. Globally, these results could suggest a possible role of global ceruloplasmin (with copper near statistical significance) and zinc deficiency in the risk for PD (perhaps related to the role of these metals in oxidative stress), despite a previous meta-analysis not showing a lower dietary intake of copper and zinc in PD patients [124].

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cells15030288/s1, Supplementary Table S1. Results of studies addressing concentrations of copper, ceruloplasmin, zinc, and manganese in brain, CSF, serum/plasma, urine, and hair in patients with Parkinson’s disease compared to controls. Supplementary Table S2. PRISMA Checklist. Supplementary Table S3. MOOSE Checklist.

Author Contributions

F.J.J.-J.: Conceptualization, Methodology, Investigation, Validation, Formal analysis, Investigation, Writing—Original Draft, Writing—Review and Editing, Project Administration. H.A.-N.: Conceptualization, Methodology, Investigation, Validation, Formal Analysis, Investigation, Writing—Original Draft, Writing—Review and Editing, Project Administration. E.G.-M.: Conceptualization, Methodology, Investigation, Validation, Formal Analysis, Investigation, Writing—Original Draft, Writing—Review and Editing, Project Administration, Obtaining Funding. M.A.M.-G.: Conceptualization, Methodology, Investigation, Validation, Formal Analysis, Investigation, Writing—Original Draft, Writing—Review and Editing, Project Administration P.S.-C.: Conceptualization, Methodology, Investigation, Validation, Formal Analysis, Investigation, Writing—Original Draft, Writing—Review and Editing, Project Administration A.C.-F.: Conceptualization, Methodology, Investigation, Validation, Formal Analysis, Investigation, Writing—Original Draft, Writing—Review and Editing, Project Administration. M.A.-S.: Conceptualization, Methodology, Investigation, Validation, Formal Analysis, Investigation, Writing—Original Draft, Writing—Review and Editing, Project Administration J.A.G.A.: Conceptualization, Methodology, Investigation, Validation, Formal Analysis, Investigation, Writing—Original Draft, Writing—Review and Editing, Project Administration, Obtaining Funding. All authors have read and agreed to the published version of the manuscript.

Funding

The work in the authors’ laboratory is supported in part by Grants PI24/01358 and PI21/01683 from Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Madrid, Spain, as well as GR24126 from Junta de Extremadura, Mérida, Spain. Partially funded with FEDER funds. The publication has been co-funded at 85% by the European Union, the European Regional Development Fund, and the Regional Government of Extremadura. Managing Authority: Spanish Ministry of Finance, GR24126.

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author and/or José A. G. Agúndez on reasonable request.

Acknowledgments

We recognize the effort of José Manuel Lorenzo Estrada (personnel of the Library of Hospital Universitario del Sureste, Arganda del Rey), who retrieved an important number of papers for us.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All authors declare that there are no financial or non-financial conflicts of interest.

References

  1. Hamidpour, S.K.; Amiri, M.; Ketabforoush, A.H.M.E.; Saeedi, S.; Angaji, A.; Tavakol, S. Unraveling Dysregulated Cell Signaling Pathways, Genetic and Epigenetic Mysteries of Parkinson’s Disease. Mol. Neurobiol. 2024, 61, 8928–8966. [Google Scholar] [CrossRef]
  2. Walecha, V.; Luthra, P.M. The Mitochondrial-Astrocyte-Neuron Triad Hypothesis in Parkinson’s Disease: A Toxic Feedback Loop of Metabolism, Aggregation, and Oxidative Stress. Neurochem. Res. 2025, 50, 317. [Google Scholar] [CrossRef]
  3. Wei, Z.; Li, X.; Li, X.; Liu, Q.; Cheng, Y. Oxidative Stress in Parkinson’s Disease: A Systematic Review and Meta-Analysis. Front. Mol. Neurosci. 2018, 11, 236. [Google Scholar] [CrossRef]
  4. Jomova, K.; Alomar, S.Y.; Valko, R.; Nepovimova, E.; Kuca, K.; Valko, M. The Role of Redox-Active Iron, Copper, Manganese, and Redox-Inactive Zinc in Toxicity, Oxidative Stress, and Human Diseases. EXCLI J. 2025, 24, 880–954. [Google Scholar] [CrossRef] [PubMed]
  5. Mezzaroba, L.; Alfieri, D.F.; Colado Simão, A.N.; Vissoci Reiche, E.M. The Role of Zinc, Copper, Manganese and Iron in Neurodegenerative Diseases. Neurotoxicology 2019, 74, 230–241. [Google Scholar] [CrossRef] [PubMed]
  6. Jiménez-Jiménez, F.J.; Alonso-Navarro, H.; García-Martín, E.; Agúndez, J.A.G. Biological Fluid Levels of Iron and Iron-Related Proteins in Parkinson’s Disease: Review and Meta-Analysis. Eur. J. Neurol. 2021, 28, 1041–1055. [Google Scholar] [CrossRef] [PubMed]
  7. Genoud, S.; Senior, A.M.; Hare, D.J.; Double, K.L. Meta-Analysis of Copper and Iron in Parkinson’s Disease Brain and Biofluids. Mov. Disord. 2020, 35, 662–671. [Google Scholar] [CrossRef]
  8. Scolari Grotto, F.; Glaser, V. Are High Copper Levels Related to Alzheimer’s and Parkinson’s Diseases? A Systematic Review and Meta-Analysis of Articles Published between 2011 and 2022. Biometals 2024, 37, 3–22. [Google Scholar] [CrossRef]
  9. Adani, G.; Filippini, T.; Michalke, B.; Vinceti, M. Selenium and Other Trace Elements in the Etiology of Parkinson’s Disease: A Systematic Review and Meta-Analysis of Case-Control Studies. Neuroepidemiology 2020, 54, 1–23. [Google Scholar] [CrossRef]
  10. Sun, H.; Liu, X.; Ge, H.; Wang, T.; Wang, Y.; Li, W. Association between Serum Zinc Levels and the Risk of Parkinson’s Disease: A Meta-Analysis. Biol. Trace Elem. Res. 2017, 179, 45–51. [Google Scholar] [CrossRef]
  11. Du, K.; Liu, M.Y.; Zhong, X.; Wei, M.J. Decreased Circulating Zinc Levels in Parkinson’s Disease: A Meta-Analysis Study. Sci. Rep. 2017, 7, 3902. [Google Scholar] [CrossRef] [PubMed]
  12. Riederer, P.; Sofic, E.; Rausch, W.D.; Schmidt, B.; Reynolds, G.P.; Jellinger, K.; Youdim, M.B. Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains. J. Neurochem. 1989, 52, 515–520. [Google Scholar] [CrossRef] [PubMed]
  13. Dexter, D.T.; Wells, F.R.; Lees, A.J.; Agid, F.; Agid, Y.; Jenner, P.; Marsden, C.D. Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson’s Disease. J. Neurochem. 1989, 52, 1830–1836. [Google Scholar] [CrossRef]
  14. Uitti, R.J.; Rajput, A.H.; Rozdilsky, B.; Bickis, M.; Wollin, T.; Yuen, W.K. Regional Metal Concentrations in Parkinson’s Disease, Other Chronic Neurological Diseases, and Control Brains. Can. J. Neurol. Sci. 1989, 16, 310–314. [Google Scholar] [CrossRef] [PubMed]
  15. Dexter, D.T.; Carayon, A.; Javoy-Agid, F.; Agid, Y.; Wells, F.R.; Daniel, S.E.; Lees, A.J.; Jenner, P.; Marsden, C.D. Alterations in the Levels of Iron, Ferritin and Other Trace Metals in Parkinson’s Disease and Other Neurodegenerative Diseases Affecting the Basal Ganglia. Brain 1991, 114, 1953–1975. [Google Scholar] [CrossRef]
  16. Loeffler, D.A.; LeWitt, P.A.; Juneau, P.L.; Sima, A.A.; Nguyen, H.U.; DeMaggio, A.J.; Brickman, C.M.; Brewer, G.J.; Dick, R.D.; Troyer, M.D.; et al. Increased Regional Brain Concentrations of Ceruloplasmin in Neurodegenerative Disorders. Brain Res. 1996, 738, 265–274. [Google Scholar] [CrossRef]
  17. Wypijewska, A.; Galazka-Friedman, J.; Bauminger, E.R.; Wszolek, Z.K.; Schweitzer, K.J.; Dickson, D.W.; Jaklewicz, A.; Elbaum, D.; Friedman, A. Iron and Reactive Oxygen Species Activity in Parkinsonian Substantia Nigra. Park. Relat. Disord. 2010, 16, 329–333. [Google Scholar] [CrossRef]
  18. Szczerbowska-Boruchowska, M.; Krygowska-Wajs, A.; Adamek, D. Elemental Micro-Imaging and Quantification of Human Substantia Nigra Using Synchrotron Radiation Based X-ray Fluorescence in Relation to Parkinson’s Disease. J. Phys. Condens. Matter 2012, 24, 244104. [Google Scholar] [CrossRef]
  19. Davies, K.M.; Bohic, S.; Carmona, A.; Ortega, R.; Cottam, V.; Hare, D.J.; Finberg, J.P.; Reyes, S.; Halliday, G.M.; Mercer, J.F.; et al. Copper Pathology in Vulnerable Brain Regions in Parkinson’s Disease. Neurobiol. Aging 2014, 35, 858–866. [Google Scholar] [CrossRef]
  20. Gardner, B.; Dieriks, B.V.; Cameron, S.; Mendis, L.H.S.; Turner, C.; Faull, R.L.M.; Curtis, M.A. Metal Concentrations and Distributions in the Human Olfactory Bulb in Parkinson’s Disease. Sci. Rep. 2017, 7, 10454. [Google Scholar] [CrossRef]
  21. Genoud, S.; Roberts, B.R.; Gunn, A.P.; Halliday, G.M.; Lewis, S.J.G.; Ball, H.J.; Hare, D.J.; Double, K.L. Subcellular Compartmentalisation of Copper, Iron, Manganese, and Zinc in the Parkinson’s Disease Brain. Metallomics 2017, 9, 1447–1455. [Google Scholar] [CrossRef] [PubMed]
  22. Mindadse, A.A.; Tschikowani, T.I. Über die Verteilung von Spurenelementen (Mangan, Kupfer, Zink und Gold) im Serum und Liquor bei Epilepsie und Parkinsonsyndrom. Dtsch. Gesundheitsw. 1967, 22, 1746–1748. [Google Scholar]
  23. Campanella, G.; Carrieri, P.; Romito, D.; Pasqual-Marsettin, E. Ferro, Transferrina, Rame e Ceruloplasmina del Siero e del Liquor nelle Malattie Extrapiramidali e nelle Miopatie Primitive. Acta Neurol. 1973, 28, 1–34. [Google Scholar]
  24. Pall, H.S.; Williams, A.C.; Blake, D.R.; Lunec, J.; Gutteridge, J.M.; Hall, M.; Taylor, A. Raised Cerebrospinal-Fluid Copper Concentration in Parkinson’s Disease. Lancet 1987, 2, 238–241. [Google Scholar] [CrossRef]
  25. Gazzaniga, G.C.; Ferraro, B.; Camerlingo, M.; Casto, L.; Viscardi, M.; Mamoli, A. A Case–Control Study of CSF Copper, Iron and Manganese in Parkinson Disease. Ital. J. Neurol. Sci. 1992, 13, 239–243. [Google Scholar] [CrossRef] [PubMed]
  26. Jiménez-Jiménez, F.J.; Molina, J.A.; Aguilar, M.V.; Meseguer, I.; Mateos-Vega, C.J.; González-Muñoz, M.J.; de Bustos, F.; Martínez-Salio, A.; Ortí-Pareja, M.; Zurdo, M.; et al. Cerebrospinal Fluid Levels of Transition Metals in Patients with Parkinson’s Disease. J. Neural Transm. 1998, 105, 497–505. [Google Scholar] [CrossRef] [PubMed]
  27. Boll, M.C.; Sotelo, J.; Otero, E.; Alcaraz-Zubeldia, M.; Rios, C. Reduced Ferroxidase Activity in the Cerebrospinal Fluid from Patients with Parkinson’s Disease. Neurosci. Lett. 1999, 265, 155–158. [Google Scholar] [CrossRef]
  28. Forte, G.; Bocca, B.; Senofonte, O.; Petrucci, F.; Brusa, L.; Stanzione, P.; Zannino, S.; Violante, N.; Alimonti, A.; Sancesario, G. Trace and Major Elements in Whole Blood, Serum, Cerebrospinal Fluid and Urine of Patients with Parkinson’s Disease. J. Neural Transm. 2004, 111, 1031–1040. [Google Scholar] [CrossRef]
  29. Qureshi, G.A.; Qureshi, A.A.; Memon, S.A.; Parvez, S.H. Impact of Selenium, Iron, Copper and Zinc in On/Off Parkinson’s Patients on L-Dopa Therapy. J. Neural Transm. Suppl. 2006, 71, 229–236. [Google Scholar] [CrossRef]
  30. Bocca, B.; Alimonti, A.; Senofonte, O.; Pino, A.; Violante, N.; Petrucci, F.; Sancesario, G.; Forte, G. Metal Changes in CSF and Peripheral Compartments of Parkinsonian Patients. J. Neurol. Sci. 2006, 248, 23–30. [Google Scholar] [CrossRef]
  31. Alimonti, A.; Bocca, B.; Pino, A.; Ruggieri, F.; Forte, G.; Sancesario, G. Elemental Profile of Cerebrospinal Fluid in Patients with Parkinson’s Disease. J. Trace Elem. Med. Biol. 2007, 21, 234–241. [Google Scholar] [CrossRef]
  32. Boll, M.C.; Alcaraz-Zubeldia, M.; Montes, S.; Rios, C. Free Copper, Ferroxidase and SOD1 Activities, Lipid Peroxidation and NO(x) Content in the CSF: A Different Marker Profile in Four Neurodegenerative Diseases. Neurochem. Res. 2008, 33, 1717–1723. [Google Scholar] [CrossRef]
  33. Hozumi, I.; Hasegawa, T.; Honda, A.; Ozawa, K.; Hayashi, Y.; Hashimoto, K.; Yamada, M.; Koumura, A.; Sakurai, T.; Kimura, A.; et al. Patterns of Levels of Biological Metals in CSF Differ among Neurodegenerative Diseases. J. Neurol. Sci. 2011, 303, 95–99. [Google Scholar] [CrossRef]
  34. Sanyal, J.; Ahmed, S.S.; Ng, H.K.; Naiya, T.; Ghosh, E.; Banerjee, T.K.; Lakshmi, J.; Guha, G.; Rao, V.R. Metallomic Biomarkers in Cerebrospinal Fluid and Serum in Patients with Parkinson’s Disease in Indian Population. Sci. Rep. 2016, 6, 35097. [Google Scholar] [CrossRef] [PubMed]
  35. Maass, F.; Michalke, B.; Leha, A.; Boerger, M.; Zerr, I.; Koch, J.C.; Tönges, L.; Bähr, M.; Lingor, P. Elemental Fingerprint as a Cerebrospinal Fluid Biomarker for the Diagnosis of Parkinson’s Disease. J. Neurochem. 2018, 145, 342–351. [Google Scholar] [CrossRef]
  36. Willkommen, D.; Lucio, M.; Schmitt-Kopplin, P.; Gazzaz, M.; Schroeter, M.; Sigaroudi, A.; Michalke, B. Species Fractionation in a Case–Control Study Concerning Parkinson’s Disease: Cu–Amino Acids Discriminate CSF of PD from Controls. J. Trace Elem. Med. Biol. 2018, 49, 164–170. [Google Scholar] [CrossRef] [PubMed]
  37. Dušek, P.; Subramanian, R.G.; Serranová, T.; Šonka, K.; Růžička, E.; Kuta, J. Blood and Cerebrospinal Fluid Metallomics Uncover Mercury, Chromium, and Iron Alterations in De Novo Parkinson’s Disease. J. Park. Dis. 2025, in press. [Google Scholar] [CrossRef]
  38. Kanabrocki, E.L.; Case, L.F.; Graham, L.; Fields, T.; Miller, E.B.; Oester, Y.T.; Kaplan, E. Non-Dialyzable Manganese and Copper Levels in Serum of Patients with Various Diseases. J. Nucl. Med. 1967, 8, 166–172. [Google Scholar] [PubMed]
  39. Chitre, V.S.; Punekar, B.D. Changes in Serum Copper and PPD-Oxidase in Different Diseases. II. Comparative Studies in Wilson’s Disease, Schizophrenia and Parkinsonism. Indian J. Med. Res. 1970, 58, 563–573. [Google Scholar]
  40. Jiménez-Jiménez, F.J.; Fernández-Calle, P.; Martínez-Vanaclocha, M.; Herrero, E.; Molina, J.A.; Vázquez, A.; Codoceo, R. Serum Levels of Zinc and Copper in Patients with Parkinson’s Disease. J. Neurol. Sci. 1992, 112, 30–33. [Google Scholar] [CrossRef]
  41. Abbott, R.A.; Cox, M.; Markus, H.; Tomkins, A. Diet, Body Size and Micronutrient Status in Parkinson’s Disease. Eur. J. Clin. Nutr. 1992, 46, 879–884. [Google Scholar]
  42. Tórsdóttir, G.; Kristinsson, J.; Sveinbjörnsdóttir, S.; Snaedal, J.; Jóhannesson, T. Copper, Ceruloplasmin, Superoxide Dismutase and Iron Parameters in Parkinson’s Disease. Pharmacol. Toxicol. 1999, 85, 239–243. [Google Scholar] [CrossRef]
  43. Kocatürk, P.A.; Akbostanci, M.C.; Tan, F.; Kavas, G.O. Superoxide Dismutase Activity and Zinc and Copper Concentrations in Parkinson’s Disease. Pathophysiology 2000, 7, 63–67. [Google Scholar] [CrossRef] [PubMed]
  44. Hegde, M.L.; Shanmugavelu, P.; Vengamma, B.; Rao, T.S.; Menon, R.B.; Rao, R.V.; Rao, K.S. Serum Trace Element Levels and the Complexity of Inter-Element Relations in Patients with Parkinson’s Disease. J. Trace Elem. Med. Biol. 2004, 18, 163–171. [Google Scholar] [CrossRef]
  45. Alimonti, A.; Ristori, G.; Giubilei, F.; Stazi, M.A.; Pino, A.; Visconti, A.; Brescianini, S.; Sepe Monti, M.; Forte, G.; Stanzione, P.; et al. Serum Chemical Elements and Oxidative Status in Alzheimer’s Disease, Parkinson Disease and Multiple Sclerosis. Neurotoxicology 2007, 28, 450–456. [Google Scholar] [CrossRef] [PubMed]
  46. Squitti, R.; Gorgone, G.; Binetti, G.; Ghidoni, R.; Pasqualetti, P.; Draicchio, F.; Albini, E.; Benedetti, L.; Lucchini, R.; Rossini, P.M. Dismetabolismo dei Metalu e Stress Ossidativo in Pazienti con Parkinson’s Disease di un’Area Industriale Esposta ad Inquinamento da Metalli. G. Ital. Med. Lav. Ergon. 2007, 29, 294–296. [Google Scholar]
  47. Gellein, K.; Syversen, T.; Steinnes, E.; Nilsen, T.I.; Dahl, O.P.; Mitrovic, S.; Duraj, D.; Flaten, T.P. Trace Elements in Serum from Patients with Parkinson’s Disease—A Prospective Case–Control Study: The Nord-Trøndelag Health Study (HUNT). Brain Res. 2008, 1219, 111–115. [Google Scholar] [CrossRef] [PubMed]
  48. Bharucha, K.J.; Friedman, J.K.; Vincent, A.S.; Ross, E.D. Lower Serum Ceruloplasmin Levels Correlate with Younger Age of Onset in Parkinson’s Disease. J. Neurol. 2009, 255, 1957–1962. [Google Scholar] [CrossRef]
  49. Nikam, S.; Nikam, P.; Ahaley, S.K.; Sontakke, A.V. Oxidative Stress in Parkinson’s Disease. Indian J. Clin. Biochem. 2009, 24, 98–101. [Google Scholar] [CrossRef]
  50. Fukushima, T.; Tan, X.; Luo, Y.; Kanda, H. Relationship between Blood Levels of Heavy Metals and Parkinson’s Disease in China. Neuroepidemiology 2010, 34, 18–24. [Google Scholar] [CrossRef]
  51. Fukushima, T.; Tan, X.; Luo, Y.; Kanda, H. Serum Vitamins and Heavy Metals in Blood and Urine, and the Correlations among Them in Parkinson’s Disease Patients in China. Neuroepidemiology 2011, 36, 240–244. [Google Scholar] [CrossRef]
  52. Fukushima, T.; Tan, X.; Luo, Y.; Wang, P.; Song, J.; Kanda, H.; Hayakawa, T.; Kumagai, T.; Kakamu, T.; Tsuji, M.; et al. Heavy Metals in Blood and Urine and Its Relation to Depressive Symptoms in Parkinson’s Disease Patients. Fukushima J. Med. Sci. 2013, 59, 76–80. [Google Scholar] [CrossRef]
  53. Fukushima, T.; Tan, X.; Luo, Y.; Wang, P.; Song, J.; Kanda, H.; Hayakawa, T.; Kumagai, T.; Kakamu, T.; Tsuji, M.; et al. Correlations among Heavy Metals in Blood and Urine and Their Relations to Depressive Symptoms in Parkinson’s Disease Patients. Fukushima J. Med. Sci. 2014, 60, 108–115. [Google Scholar] [CrossRef] [PubMed]
  54. Arnal, N.; Cristalli, D.O.; de Alaniz, M.J.; Marra, C.A. Clinical Utility of Copper, Ceruloplasmin, and Metallothionein Plasma Determinations in Human Neurodegenerative Patients and Their First-Degree Relatives. Brain Res. 2010, 1319, 118–130. [Google Scholar] [CrossRef]
  55. Henkin, R.I.; Potolicchio, S.J.; Levy, L.M.; Moharram, R.; Velicu, I.; Martin, B.M. Carbonic Anhydrase I, II, and VI, Blood Plasma, Erythrocyte and Saliva Zinc and Copper Increase after Repetitive Transcranial Magnetic Stimulation. Am. J. Med. Sci. 2010, 339, 249–257. [Google Scholar] [CrossRef] [PubMed]
  56. Baillet, A.; Chanteperdrix, V.; Trocmé, C.; Casez, P.; Garrel, C.; Besson, G. The Role of Oxidative Stress in Amyotrophic Lateral Sclerosis and Parkinson’s Disease. Neurochem. Res. 2010, 35, 1530–1537. [Google Scholar] [CrossRef]
  57. Ahmed, S.S.; Santosh, W. Metallomic Profiling and Linkage Map Analysis of Early Parkinson’s Disease: A New Insight to Aluminum Marker for the Possible Diagnosis. PLoS ONE 2010, 5, e11252. [Google Scholar] [CrossRef]
  58. Ling, H.; Bhidayasiri, R. Reduced Serum Caeruloplasmin Levels in Non-Wilsonian Movement Disorders. Eur. Neurol. 2011, 66, 123–127. [Google Scholar] [CrossRef] [PubMed]
  59. McIntosh, K.G.; Cusack, M.J.; Vershinin, A.; Chen, Z.W.; Zimmerman, E.A.; Molho, E.S.; Celmins, D.; Parsons, P.J. Evaluation of a Prototype Point-of-Care Instrument Based on Monochromatic X-Ray Fluorescence Spectrometry: Potential for Monitoring Trace Element Status of Subjects with Neurodegenerative Disease. J. Toxicol. Environ. Health A 2012, 75, 1253–1268. [Google Scholar] [CrossRef]
  60. Mariani, S.; Ventriglia, M.; Simonelli, I.; Donno, S.; Bucossi, S.; Vernieri, F.; Melgari, J.M.; Pasqualetti, P.; Rossini, P.M.; Squitti, R. Fe and Cu Do Not Differ in Parkinson’s Disease: A Replication Study plus Meta-Analysis. Neurobiol. Aging 2013, 34, 632–633. [Google Scholar] [CrossRef]
  61. Younes-Mhenni, S.; Aissi, M.; Mokni, N.; Boughammoura-Bouatay, A.; Chebel, S.; Frih-Ayed, M.; Kerkeni, A.; Bost, M.; Chazot, G.; Sfar, M.T.; et al. Serum Copper, Zinc and Selenium Levels in Tunisian Patients with Parkinson’s Disease. Tunis. Med. 2013, 91, 402–405. [Google Scholar]
  62. Zhao, H.W.; Lin, J.; Wang, X.B.; Cheng, X.; Wang, J.Y.; Hu, B.L.; Zhang, Y.; Zhang, X.; Zhu, J.H. Assessing Plasma Levels of Selenium, Copper, Iron and Zinc in Patients of Parkinson’s Disease. PLoS ONE 2013, 8, e83060. [Google Scholar] [CrossRef] [PubMed]
  63. Kumudini, N.; Uma, A.; Devi, Y.P.; Naushad, S.M.; Mridula, R.; Borgohain, R.; Kutala, V.K. Association of Parkinson’s Disease with Altered Serum Levels of Lead and Transition Metals among South Indian Subjects. Indian J. Biochem. Biophys. 2014, 51, 121–126. [Google Scholar]
  64. Meamar, R.; Nikyar, H.; Dehghani, L.; Basiri, K.; Ghazvini, M.R. Assessing Plasma Levels of Iron, Zinc and Copper in Iranian Parkinson’s Disease Patients. Adv. Biomed. Res. 2016, 5, 31. [Google Scholar] [CrossRef]
  65. Song, Y.S.; Kim, J.M.; Kim, K.J.; Yun, J.Y.; Kim, S.E. Serum Ceruloplasmin and Striatal Dopamine Transporter Density in Parkinson Disease: Comparison with 123I-FP-CIT SPECT. Clin. Nucl. Med. 2017, 42, 675–679. [Google Scholar] [CrossRef]
  66. Gangania, M.K.; Batra, J.; Kushwaha, S.; Agarwal, R. Role of Iron and Copper in the Pathogenesis of Parkinson’s Disease. Indian J. Clin. Biochem. 2017, 32, 353–356. [Google Scholar] [CrossRef]
  67. Karpenko, M.N.; Ilyicheva, E.Y.; Muruzheva, Z.M.; Milyukhina, I.V.; Orlov, Y.A.; Puchkova, L.V. Role of Copper Dyshomeostasis in the Pathogenesis of Parkinson’s Disease. Bull. Exp. Biol. Med. 2018, 164, 596–600. [Google Scholar] [CrossRef] [PubMed]
  68. Ilyechova, E.Y.; Miliukhina, I.V.; Orlov, I.A.; Muruzheva, Z.M.; Puchkova, L.V.; Karpenko, M.N. A Low Blood Copper Concentration Is a Co-Morbidity Burden Factor in Parkinson’s Disease Development. Neurosci. Res. 2018, 135, 54–62. [Google Scholar] [CrossRef] [PubMed]
  69. Kim, M.J.; Oh, S.B.; Kim, J.; Kim, K.; Ryu, H.S.; Kim, M.S.; Ayton, S.; Bush, A.I.; Lee, J.Y.; Chung, S.J. Association of Metals with the Risk and Clinical Characteristics of Parkinson’s Disease. Park. Relat. Disord. 2018, 55, 117–121. [Google Scholar] [CrossRef]
  70. Ajsuvakova, O.P.; Tinkov, A.A.; Willkommen, D.; Skalnaya, A.A.; Danilov, A.B.; Pilipovich, A.A.; Aschner, M.; Skalny, A.V.; Michalke, B.; Skalnaya, M.G. Assessment of Copper, Iron, Zinc and Manganese Status and Speciation in Patients with Parkinson’s Disease: A Pilot Study. J. Trace Elem. Med. Biol. 2020, 59, 126423. [Google Scholar] [CrossRef]
  71. Fattah, A.; Amiri, F.; Mohammadian, M.; Alipourfard, I.; Valilo, M.; Taheraghdam, A.; Hemmati-Dinarvand, M. Dysregulation of Body Antioxidant Content Is Related to Initiation and Progression of Parkinson’s Disease. Neurosci. Lett. 2020, 736, 135297. [Google Scholar] [CrossRef] [PubMed]
  72. Barmaki, H.; Morovati, A.; Eydivandi, Z.; Jafari Naleshkenani, F.; Saedi, S.; Musavi, H.; Abbasi, M.; Hemmati-Dinarvand, M. The Association between Serum Oxidative Stress Indexes and Pathogenesis of Parkinson’s Disease in the Northwest of Iran. Iran. J. Public Health 2021, 50, 606–615. [Google Scholar] [CrossRef] [PubMed]
  73. Tripathi, C.B.; Gangania, M.; Kushwaha, S.; Agarwal, R. Evidence-Based Discriminant Analysis: A New Insight into Iron Profile for the Diagnosis of Parkinson’s Disease. Ann. Indian Acad. Neurol. 2021, 24, 234–238. [Google Scholar] [CrossRef]
  74. Lee, J.; Park, S.; Jang, W. Serum Zinc Deficiency Could Be Associated with Dementia Conversion in Parkinson’s Disease. Front. Aging Neurosci. 2023, 15, 1132907. [Google Scholar] [CrossRef]
  75. Kim, J.E.; Lee, H.S.; Jang, W. Serum Zinc Deficiency Is a Potential Risk Factor for the Occurrence of Levodopa-Induced Dyskinesia in Drug-Naïve Parkinson’s Disease. Front. Aging Neurosci. 2023, 15, 1282367. [Google Scholar] [CrossRef]
  76. Melek, İ.M.; Kuş, B.; Kaptan, Z.; Petekkaya, E. Correlation of Metal Ions with Specific Brain Region Volumes in Neurodegenerative Diseases. Turk. J. Med. Sci. 2023, 53, 1465–1475. [Google Scholar] [CrossRef]
  77. Shan, C.; Zheng, Q.; Li, M.; Ge, Y.; Bian, J.; Huang, Z.; Guo, Z.; Jiang, Y.; Xu, P.; Lu, S.; et al. Exploring the Interactions of Urinary Metals and the Mediating Role of Oxidative Stress in Parkinson’s Disease Risk: An Epidemiological Study in the Elderly. Environ. Sci. Process. Impacts 2025, 27, 1439–1447. [Google Scholar] [CrossRef]
  78. Forte, G.; Alimonti, A.; Violante, N.; Di Gregorio, M.; Senofonte, O.; Petrucci, F.; Sancesario, G.; Bocca, B. Calcium, Copper, Iron, Magnesium, Silicon and Zinc Content of Hair in Parkinson’s Disease. J. Trace Elem. Med. Biol. 2005, 19, 195–201. [Google Scholar] [CrossRef]
  79. Stefano, F.; Cinzia, N.; Marco, P.; Marco, G.; Rita, G.; Augusto, F.; Rosita, G. Hair Microelement Profile as a Prognostic Tool in Parkinson’s Disease. Toxics 2016, 4, 27. [Google Scholar] [CrossRef]
  80. Loeffler, D.A.; Sima, A.A.; LeWitt, P.A. Ceruloplasmin Immunoreactivity in Neurodegenerative Disorders. Free Radic. Res. 2001, 35, 111–118. [Google Scholar] [CrossRef]
  81. Loeffler, D.A.; DeMaggio, A.J.; Juneau, P.L.; Brickman, C.M.; Mashour, G.A.; Finkelman, J.H.; Pomara, N.; LeWitt, P.A. Ceruoplasmin Is Increased in Cerebrospinal Fluid in Alzheimer’s Disease but Not Parkinson’s Disease. Alzheimer Dis. Assoc. Disord. 1994, 8, 190–197. [Google Scholar] [CrossRef]
  82. Molina-Arjona, J.A.; de Bustos, F.; Benito-León, J.; Jiménez-Jiménez, F.J.; Rodríguez, J.; Trincado, R.; Porta-Etessan, J.; Vega, S.; Bermejo, F. Serum Pro-Oxidant and Antioxidant Factors and Risk of Parkinson’s Disease: A Population Study. Rev. Neurol. 1999, 29, 12–15. [Google Scholar]
  83. Tórsdóttir, G.; Sveinbjörnsdóttir, S.; Kristinsson, J.; Snaedal, J.; Jóhannesson, T. Ceruloplasmin and Superoxide Dismutase (SOD1) in Parkinson’s Disease: A Follow-Up Study. J. Neurol. Sci. 2006, 241, 53–58. [Google Scholar] [CrossRef]
  84. Jin, L.; Wang, J.; Zhao, L.; Jin, H.; Fei, G.; Zhang, Y.; Zeng, M.; Zhong, C. Decreased Serum Ceruloplasmin Levels Characteristically Aggravate Nigral Iron Deposition in Parkinson’s Disease. Brain 2011, 134, 50–58. [Google Scholar] [CrossRef]
  85. Zhao, N.; Jin, L.; Fei, G.; Zheng, Z.; Zhong, C. Serum microRNA-133b Is Associated with Low Ceruloplasmin Levels in Parkinson’s Disease. Park. Relat. Disord. 2014, 20, 1177–1180. [Google Scholar] [CrossRef]
  86. Xu, W.; Zhi, Y.; Yuan, Y.; Zhang, B.; Shen, Y.; Zhang, H.; Zhang, K.; Xu, Y. Correlations between Abnormal Iron Metabolism and Non-Motor Symptoms in Parkinson’s Disease. J. Neural Transm. 2018, 125, 1027–1032. [Google Scholar] [CrossRef]
  87. Si, Q.Q.; Yuan, Y.S.; Zhi, Y.; Tong, Q.; Zhang, L.; Zhang, K. Plasma Transferrin Level Correlates with the Tremor-Dominant Phenotype of Parkinson’s Disease. Neurosci. Lett. 2018, 684, 42–46. [Google Scholar] [CrossRef] [PubMed]
  88. Bakeberg, M.C.; Riley, M.; Byrnes, M.; Jefferson, A.; Ghosh, S.; Horne, M.K.; McGregor, S.; Stell, R.; Walters, S.; Evans, T.; et al. Elevated Serum Ceruloplasmin Levels Are Associated with Higher Impulsivity in People with Parkinson’s Disease. Park. Dis. 2020, 2020, 8296203. [Google Scholar] [CrossRef] [PubMed]
  89. Hirsch, E.C.; Brandel, J.P.; Galle, P.; Javoy-Agid, F.; Agid, Y. Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson’s Disease: An X-Ray Microanalysis. J. Neurochem. 1991, 56, 446–451. [Google Scholar] [CrossRef] [PubMed]
  90. Mann, V.M.; Cooper, J.M.; Daniel, S.E.; Srai, K.; Jenner, P.; Marsden, C.D.; Schapira, A.H. Complex I, Iron, and Ferritin in Parkinson’s Disease Substantia Nigra. Ann. Neurol. 1994, 36, 876–881. [Google Scholar] [CrossRef]
  91. Popescu, B.F.; George, M.J.; Bergmann, U.; Garachtchenko, A.V.; Kelly, M.E.; McCrea, R.P.; Lüning, K.; Devon, R.M.; George, G.N.; Hanson, A.D.; et al. Mapping Metals in Parkinson’s and Normal Brain Using Rapid-Scanning X-Ray Fluorescence. Phys. Med. Biol. 2009, 54, 651–663. [Google Scholar] [CrossRef]
  92. Brewer, G.J.; Kanzer, S.H.; Zimmerman, E.A.; Molho, E.S.; Celmins, D.F.; Heckman, S.M.; Dick, R. Subclinical Zinc Deficiency in Alzheimer’s Disease and Parkinson’s Disease. Am. J. Alzheimers Dis. Other Demen. 2010, 25, 572–575. [Google Scholar] [CrossRef]
  93. Verma, A.K.; Keshari, A.K.; Raj, J.; Kumari, R.; Kumar, T.; Sharma, V.; Singh, T.B.; Srivastava, S.; Srivastava, R. Prolidase-Associated Trace Elements (Mn, Zn, Co, and Ni) in Patients with Parkinson’s Disease. Biol. Trace Elem. Res. 2016, 171, 48–53. [Google Scholar] [CrossRef] [PubMed]
  94. Matsuyama, H.; Matsuura, K.; Ishikawa, H.; Hirata, Y.; Kato, N.; Niwa, A.; Narita, Y.; Tomimoto, H. Correlation between Serum Zinc Levels and Levodopa in Parkinson’s Disease. Nutrients 2021, 13, 4114. [Google Scholar] [CrossRef] [PubMed]
  95. Dos Santos, A.B.; Kohlmeier, K.A.; Rocha, M.E.; Barreto, G.E.; Barreto, J.A.; de Souza, A.C.A.; Bezerra, M.A. Hair in Parkinson’s Disease Patients Exhibits Differences in Calcium, Iron and Zinc Concentrations Measured by Flame Atomic Absorption Spectrometry. J. Trace Elem. Med. Biol. 2018, 47, 134–139. [Google Scholar] [CrossRef] [PubMed]
  96. Larsen, N.A.; Pakkenberg, H.; Damsgaard, E.; Heydorn, K.; Wold, S. Distribution of Arsenic, Manganese, and Selenium in the Human Brain in Chronic Renal Insufficiency, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis. J. Neurol. Sci. 1981, 51, 437–446. [Google Scholar] [CrossRef]
  97. Dos Santos, A.B.; Bezerra, M.A.; Rocha, M.E.; Barreto, G.E.; Kohlmeier, K.A. Higher Zinc Concentrations in Hair of Parkinson’s Disease Are Associated with Psychotic Complications and Depression. J. Neural Transm. 2019, 126, 1291–1301. [Google Scholar] [CrossRef]
  98. Jiménez-Jiménez, F.J.; Molina, J.A.; Aguilar, M.V.; Arrieta, F.J.; Jorge-Santamaría, A.; Cabrera-Valdivia, F.; Ayuso-Peralta, L.; Rabasa, M.; Vázquez, A.; García-Albea, E.; et al. Serum and Urinary Manganese Levels in Patients with Parkinson’s Disease. Acta Neurol. Scand. 1995, 91, 317–320. [Google Scholar] [CrossRef]
  99. Balduzzi, S.; Rücker, G.; Schwarzer, G. How to Perform a Meta-Analysis with R: A Practical Tutorial. Evid.-Based Ment. Health 2019, 22, 153–160. [Google Scholar] [CrossRef]
  100. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009, 6, e1000097. [Google Scholar] [CrossRef]
  101. Stroup, D.F.; Berlin, J.A.; Morton, S.C.; Olkin, I.; Williamson, G.D.; Rennie, D.; Moher, D.; Becker, B.J.; Sipe, T.A.; Thacker, S.B. Meta-Analysis of Observational Studies in Epidemiology: A Proposal for Reporting. JAMA 2000, 283, 2008–2012. [Google Scholar] [CrossRef] [PubMed]
  102. Jiménez-Jiménez, F.J.; Ayuso, P.; Alonso-Navarro, H.; Calleja, M.; Díez-Fairén, M.; Álvarez, I.; Pastor, P.; Plaza-Nieto, J.F.; Navarro-Muñoz, S.; Turpín-Fenoll, L.; et al. Serum Trace Elements Concentrations in Patients with Restless Legs Syndrome. Antioxidants 2022, 11, 272. [Google Scholar] [CrossRef]
  103. Auclair, S.; Feillet-Coudray, C.; Coudray, C.; Schneider, S.; Muckenthaler, M.U.; Mazur, A. Mild Copper Deficiency Alters Gene Expression of Proteins Involved in Iron Metabolism. Blood Cells Mol. Dis. 2006, 36, 15–20. [Google Scholar] [CrossRef]
  104. Walke, G.; Kumar, R.; Wittung-Stafshede, P. Copper Ion Incorporation in α-Synuclein Amyloids. Protein Sci. 2024, 33, e4956. [Google Scholar] [CrossRef]
  105. Genchi, G.; Catalano, A.; Carocci, A.; Sinicropi, M.S.; Lauria, G. Copper, Cuproptosis, and Neurodegenerative Diseases. Int. J. Mol. Sci. 2025, 26, 9173. [Google Scholar] [CrossRef]
  106. Zecca, L.; Bellei, C.; Costi, P.; Albertini, A.; Monzani, E.; Casella, L.; Gallorini, M.; Bergamaschi, L.; Moscatelli, A.; Turro, N.J.; et al. New Melanic Pigments in the Human Brain That Accumulate in Aging and Block Environmental Toxic Metals. Proc. Natl. Acad. Sci. USA 2008, 105, 17567–17572. [Google Scholar] [CrossRef] [PubMed]
  107. Kastner, A.; Hirsch, E.C.; Lejeune, O.; Javoy-Agid, F.; Rascol, O.; Agid, Y. Is the Vulnerability of Neurons in the Substantia Nigra of Patients with Parkinson’s Disease Related to Their Neuromelanin Content? J. Neurochem. 1992, 59, 1080–1089. [Google Scholar] [CrossRef]
  108. Zecca, L.; Stroppolo, A.; Gatti, A.; Tampellini, D.; Toscani, M.; Gallorini, M.; Giaveri, G.; Arosio, P.; Santambrogio, P.; Fariello, R.G.; et al. The Role of Iron and Copper Molecules in the Neuronal Vulnerability of Locus Coeruleus and Substantia Nigra during Aging. Proc. Natl. Acad. Sci. USA 2004, 101, 9843–9848. [Google Scholar] [CrossRef]
  109. Kristinsson, J.; Snaedal, J.; Tórsdóttir, G.; Jóhannesson, T. Ceruloplasmin and Iron in Alzheimer’s Disease and Parkinson’s Disease: A Synopsis of Recent Studies. Neuropsychiatr. Dis. Treat. 2012, 8, 515–521. [Google Scholar] [CrossRef]
  110. Popescu, C.; Munteanu, C.; Spînu, A.; Andone, I.; Bistriceanu, R.; Postoiu, R.; Suciu, A.; Giuvara, S.; Vlădulescu-Trandafir, A.I.; Aurelian, S.M.; et al. Actual Data on Essential Trace Elements in Parkinson’s Disease. Nutrients 2025, 17, 1852. [Google Scholar] [CrossRef] [PubMed]
  111. Byrd, E.J.; Rowlinson, B.; Crossley, J.A.; Brockwell, D.J.; Ross, J.F.; Radford, S.E.; Sobott, F. Zn2+ Binding Shifts the Conformational Ensemble of α-Synuclein Monomers toward Accelerated Amyloid Formation. J. Am. Chem. Soc. 2025, 147, 36464–36477. [Google Scholar] [CrossRef] [PubMed]
  112. Du, K.; Liu, M.Y.; Pan, Y.Z.; Zhong, X.; Wei, M.J. Association of Circulating Manganese Levels with Parkinson’s Disease: A Meta-Analysis. Neurosci. Lett. 2018, 665, 92–98. [Google Scholar] [CrossRef]
  113. Tarohda, T.; Ishida, Y.; Kawai, K.; Yamamoto, M.; Amano, R. Regional Distributions of Manganese, Iron, Copper, and Zinc in the Brains of 6-Hydroxydopamine-Induced Parkinsonian Rats. Anal. Bioanal. Chem. 2005, 383, 224–234. [Google Scholar] [CrossRef] [PubMed]
  114. Wang, J.; Bi, M.; Xie, J. Ceruloplasmin Is Involved in the Nigral Iron Accumulation of 6-OHDA-Lesioned Rats. Cell. Mol. Neurobiol. 2015, 35, 661–668. [Google Scholar] [CrossRef] [PubMed]
  115. Matusch, A.; Depboylu, C.; Palm, C.; Wu, B.; Höglinger, G.U.; Schäfer, M.K.; Becker, J.S. Cerebral Bioimaging of Cu, Fe, Zn, and Mn in the MPTP Mouse Model of Parkinson’s Disease Using Laser Ablation ICP-MS. J. Am. Soc. Mass Spectrom. 2010, 21, 161–171. [Google Scholar] [CrossRef]
  116. Youdim, M.B.; Grünblatt, E.; Mandel, S. The Copper Chelator D-Penicillamine Does Not Attenuate MPTP-Induced Dopamine Depletion in Mice. J. Neural Transm. 2007, 114, 205–209. [Google Scholar] [CrossRef]
  117. Taylor, A.; Bryant, T.N. Comparison of procedures for determination of copper and zinc in serum by atomic absorption spectroscopy. Clin. Chim. Acta 1981, 110, 83–90. [Google Scholar] [CrossRef] [PubMed]
  118. van Beek, H.; Greefkes, H.C.; Baars, A.J. Determination of copper, iron, manganese, lead and cadmium in automatically wet-digested animal tissue by graphite-furnace atomic-absorption spectrometry with Zeeman background correction. Talanta 1987, 34, 580–582. [Google Scholar] [CrossRef]
  119. Dipietro, E.S.; Bashor, M.M.; Stroud, P.E.; Smarr, B.J.; Burgess, B.J.; Turner, W.E.; Neese, J.W. Comparison of an inductively coupled plasma–atomic emission spectrometry method for the determination of calcium, magnesium, sodium, potassium, copper and zinc with atomic absorption spectroscopy and flame photometry methods. Sci. Total Environ. 1988, 74, 249–262. [Google Scholar] [CrossRef]
  120. Cerchiaro, G.; Manieri, T.M.; Bertuchi, F.R. Analytical methods for copper, zinc and iron quantification in mammalian cells. Metallomics 2013, 5, 1336–1345. [Google Scholar] [CrossRef]
  121. Gordon, S.J.V.; Xiao, Y.; Paskavitz, A.L.; Navarro-Tito, N.; Navea, J.G.; Padilla-Benavides, T. Atomic absorbance spectroscopy to measure intracellular zinc pools in mammalian cells. J. Vis. Exp. 2019, 147, e59519. [Google Scholar] [CrossRef]
  122. El Hosry, L.; Sok, N.; Richa, R.; Al Mashtoub, L.; Cayot, P.; Bou-Maroun, E. Sample preparation and analytical techniques in the determination of trace elements in food: A review. Foods 2023, 12, 895. [Google Scholar] [CrossRef] [PubMed]
  123. Shaikh, R.; Uzgare, A.S. Tracing elements with precision: A review of inductively coupled plasma mass spectrometry (ICP-MS). Int. J. Chem. Res. 2026, 10, 26–34. [Google Scholar] [CrossRef]
  124. Cheng, P.; Yu, J.; Huang, W.; Bai, S.; Zhu, X.; Qi, Z.; Shao, W.; Xie, P. Dietary Intake of Iron, Zinc, Copper, and Risk of Parkinson’s Disease: A Meta-Analysis. Neurol. Sci. 2015, 36, 2269–2275. [Google Scholar] [CrossRef] [PubMed]
Cells 15 00288 g001
Figure 1. Flowchart for selection of studies.
Figure 1. Flowchart for selection of studies.
Cells 15 00288 g001
Cells 15 00288 g002
Figure 2. Meta-analyses of studies on concentrations of copper [12,13,14,15,17,19] in the substantia nigra (a), caudate nuclei (b), putamen (total) (c), globus pallidus medialis (d), globus pallidus medialis (e), cerebellum (f), and cerebral cortex (g) in PD patients and controls.
Figure 2. Meta-analyses of studies on concentrations of copper [12,13,14,15,17,19] in the substantia nigra (a), caudate nuclei (b), putamen (total) (c), globus pallidus medialis (d), globus pallidus medialis (e), cerebellum (f), and cerebral cortex (g) in PD patients and controls.
Cells 15 00288 g002
Cells 15 00288 g003
Figure 3. Meta-analysis of studies measuring CSF (a), serum/plasma (b), whole blood (c), urine (d), and hair (e) copper concentrations in PD patients and controls [23,24,25,26,27,28,29,30,31,33,34,35,36,37,38,39,40,41,42,43,44,46,47,48,49,50,51,52,54,55,56,57,59,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79].
Figure 3. Meta-analysis of studies measuring CSF (a), serum/plasma (b), whole blood (c), urine (d), and hair (e) copper concentrations in PD patients and controls [23,24,25,26,27,28,29,30,31,33,34,35,36,37,38,39,40,41,42,43,44,46,47,48,49,50,51,52,54,55,56,57,59,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79].
Cells 15 00288 g003
Cells 15 00288 g004
Figure 4. Meta-analysis of studies measuring serum or plasma ceruloplasmin levels in PD patients and controls [23,40,42,46,48,54,58,65,66,67,68,73,82,83,84,85,86,87,88].
Figure 4. Meta-analysis of studies measuring serum or plasma ceruloplasmin levels in PD patients and controls [23,40,42,46,48,54,58,65,66,67,68,73,82,83,84,85,86,87,88].
Cells 15 00288 g004
Cells 15 00288 g005
Figure 5. Meta-analyses of studies on concentrations of zinc [12,13,14,15,19] in the substantia nigra (a), caudate nuclei (b), putamen (total) (c), globus pallidus medialis (d), globus pallidus medialis (e), cerebellum (f), and cerebral cortex (g) in PD patients and controls.
Figure 5. Meta-analyses of studies on concentrations of zinc [12,13,14,15,19] in the substantia nigra (a), caudate nuclei (b), putamen (total) (c), globus pallidus medialis (d), globus pallidus medialis (e), cerebellum (f), and cerebral cortex (g) in PD patients and controls.
Cells 15 00288 g005
Cells 15 00288 g006
Figure 6. Meta-analysis of studies measuring CSF (a), serum/plasma (b), whole blood (c), urine (d), and hair (e) zinc concentrations in PD patients and controls [26,28,29,30,31,33,34,35,36,37,40,41,43,44,46,47,49,50,51,52,53,55,56,57,59,61,62,64,69,70,71,72,75,76,77,92,93,94,95,97].
Figure 6. Meta-analysis of studies measuring CSF (a), serum/plasma (b), whole blood (c), urine (d), and hair (e) zinc concentrations in PD patients and controls [26,28,29,30,31,33,34,35,36,37,40,41,43,44,46,47,49,50,51,52,53,55,56,57,59,61,62,64,69,70,71,72,75,76,77,92,93,94,95,97].
Cells 15 00288 g006
Cells 15 00288 g007
Figure 7. Meta-analysis of studies measuring CSF (a), serum/plasma (b), whole blood (c), urine (d), and hair (e) manganese concentrations in PD patients and controls [24,25,26,28,30,31,33,34,35,36,37,38,44,47,50,51,52,53,57,63,70,74,75,77,79,93,98].
Figure 7. Meta-analysis of studies measuring CSF (a), serum/plasma (b), whole blood (c), urine (d), and hair (e) manganese concentrations in PD patients and controls [24,25,26,28,30,31,33,34,35,36,37,38,44,47,50,51,52,53,57,63,70,74,75,77,79,93,98].
Cells 15 00288 g007
Table 1. Search strategy. The numbers in the cell correspond to the items found in the search performed with PubMed and Web of Science (Core Collection) on 29 November 2025.
Table 1. Search strategy. The numbers in the cell correspond to the items found in the search performed with PubMed and Web of Science (Core Collection) on 29 November 2025.
CopperCeruloplasminZincManganese
Brain34693298485
Cerebrospinal fluid30231922
Serum86595650
Plasma70224967
Blood1174895132
Urine2071230
Hair141713
Table 2. Studies assessing brain, CSF, serum/plasma, whole blood, urine, and hair concentrations of copper, ceruloplasmin, zinc, and manganese in patients with Parkinson’s disease and controls. Data from column “main results (2)” express degree of increase (+) or decrease (−) from 1 to 3, with 0 meaning differences are non-significant. For details see Supplementary Table S1.
Table 2. Studies assessing brain, CSF, serum/plasma, whole blood, urine, and hair concentrations of copper, ceruloplasmin, zinc, and manganese in patients with Parkinson’s disease and controls. Data from column “main results (2)” express degree of increase (+) or decrease (−) from 1 to 3, with 0 meaning differences are non-significant. For details see Supplementary Table S1.
Copper
TissueAuthor, Year [Ref]MethodMain ResultsMain Results (2)Comments/
Observations
BrainRiederer et al., 1989 [12]Atomic absorption spectrophotometrySignificant increase in the raphe plus reticular formation and red nucleus in PD brains, and non-significant differences in other brain areas, including substantia nigra, caudate, putamen, and globus pallidus.3− for raphe, reticular formation and red nucleusData obtained as estimated from a graphic.
Dexter et al., 1989 [13]Inductively coupled
plasma spectroscopy		Significant decrease in substantia nigra from PD brains (34–45%). Non-significant differences between PD and controls in cerebellum, cerebral cortex, caudate nucleus, putamen, and globus pallidus.3− for substantia nigraData obtained as estimated from a graphic.
Uitti et al., 1989 [14]Atomic emission spectroscopy and atomic absorption spectrophotometrySignificant decrease in the substantia nigra from PD brains, and non-significant differences with controls in the frontal cortex, caudate nucleus, and cerebellum.3− for substantia nigra
Dexter et al., 1991 [15]Inductively coupled
plasma spectroscopy		Significant decrease in the substantia nigra from PD brains. Non-significant differences between PD and controls in cerebellum, cerebral cortex (Brodmann
area 10), caudate nucleus, putamen, and globus pallidus.		3− for substantia nigra
Loeffler et al., 1996 [16]Flame atomic absorption spectrophotometrySignificant decrease in caudate from PD brains. Non-significant differences between PD and elderly controls in the substantia nigra, putamen, and frontal cortex.2− for caudateData expressed in ng/μg of protein. Not included in meta-analysis.
Wypijewska et al., 2010 [17]Electrothermal atomic absorption spectrometry Significant decrease in the substantia nigra from PD patients.3− for caudate
Szczerbowska-Boruchoswska et al., 2012 [18]Synchrotron radiation-based X-ray fluorescence (SRXRF)Non-significant differences between PD and controls.0Data expressed in Cu mass fraction in the substantia nigra. Not included in the meta-analysis.
Davies et al., 2014 [19]Synchrotron radiation x-ray fluorescence microscopy
(SRXFM) and particle-induced x-ray emission (PIXE) microscopy		Significant decrease in the substantia nigra and locus ceruleus from PD patients. Non-significant differences between PD and controls in the occipital cortex.3− for substantia nigra and locus ceruleus
Gardner et al., 2017 [20]Inductively coupled
plasma spectroscopy		Non-significant differences between PD and controls in the olfactory bulb and olfactory tract.0
Genoud et al., 2017 [21]Inductively coupled
plasma spectroscopy		Significant decrease in the substantia nigra from PD patients (54%). Non-significant differences between PD and controls in the occipital cortex and fusiform gyrus.3− in substantia nigraFull data not available. Not included in the meta-analysis.
CSFMindadse & Tschikowani, 1967 [22]Not availableNot available Unable to get this article; abstract not available.
Campanella et al., 1973 [23]Colorimetric methodNon-significant differences between PD patients and controls.0
Pall et al., 1987 [24]Electrochemical atomization/atomic absorption spectrophotometrySignificant increase in PD patients compared to controls.3+Controls were subjects with neurological diseases who had a clinical indication for lumbar puncture. Estimation from a graphic.
Gazzaniga et al., 1992 [25]Atomic absorption
spectrophotometry with electrothermal
atomization		Non-significant differences between PD patients and controls.0
Jiménez-Jiménez et al., 1998 [26]Flame atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0Controls were subjects with neurological diseases who had a clinical indication for lumbar puncture.
Boll et al., 1999 [27]Atomic absorption
spectrophotometry		Non-significant differences between PD patients and controls.0
Forte et al., 2004 [28]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Qureshi et al., 2006 [29]Atomic absorption
spectrophotometry with an electrothermal atomizer 		Non-significant differences between PD patients and controls.0
Bocca et al., 2006 [30]Inductively coupled plasma atomic emission spectrometry Non-significant differences between PD patients and controls.0Data obtained as estimated from a graphic.
Alimonti et al., 2007 [31]Inductively coupled plasma mass spectrometry and sector field inductively coupled Plasma Mass SpectrometryNon-significant differences between PD patients and controls.0
Boll et al., 2008 [32]Graphite furnace atomic absorption spectrophotometrySignificant increase in PD patients compared to controls.3+Measurement of free (and not total) copper. This article was excluded from meta-analysis.
Hozumi et al., 2011 [33]Inductively coupled
plasma spectroscopy		Significant increase in PD patients.3+
Sanyal et al., 2016 [34]Atomic absorption spectrophotometry and flame atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0
Maass et al., 2018 [35]Inductively
coupled plasma-sector field mass spectrometry		Non-significant differences between PD patients and controls.0
Willkommen et al., 2018 [36]Size-exclusion chromatography hyphenated to inductively coupled plasma mass spectrometry (SEC-ICP-MS)Non-significant differences between PD patients and controls.0
Dušek et al., 2025 [37]Inductively coupled
plasma spectroscopy		Significant decrease in PD patients.1−
Serum/PlasmaMindadse & Tschikowani, 1967 [22]Not availableNot available Unable to get this article; abstract not available.
Kanabrocki et al., 1967 [38]RCL 512-Channel Analyzer (an instrument used in nuclear and radiation spectroscopy)Non-significant differences between PD patients and controls.0
Chitre & Punekar, 1970 [39]Iodometric redox titrationSignificant increase in PD patients compared to controls.3+
Campanella et al., 1973 [23]Colorimetric methodsNon-significant differences between PD patients and controls.0
Jiménez-Jiménez et al., 1992 [40]Flame atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0
Abbott et al., 1992 [41] (plasma)Atomic absorption spectrophotometryNon-significant differences between PD patients and controls.
Jiménez-Jiménez et al., 1998 [26]Flame atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0Controls were subjects with neurological diseases who had a clinical indication for lumbar puncture. PD patients and controls were not the same as in [CMZ-14].
Tórsdóttir et al., 1999 [42] (plasma)Atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0
Kocatürk et al., 2000 [43] (plasma)Atomic absorption spectrophotometrySignificant increase in PD patients compared to controls.
Forte et al., 2004 [28]Inductively Coupled Plasma Atomic Emission SpectrometrySignificant decrease in PD patients compared to controls.2+
Hegde et al., 2004 [44]Inductively Coupled Plasma Atomic Emission SpectrometrySignificant increase in PD patients compared to controls.2−
Qureshi et al., 2006 [29]Atomic absorption
spectrophotometry with an electrothermal atomizer 		Non-significant differences between PD patients and controls.0
Bocca et al., 2006 [30]Inductively Coupled Plasma Atomic Emission SpectrometrySignificant decrease in PD patients compared to controls.1−
Alimonti et al., 2007 [45]Inductively Coupled Plasma Atomic Emission SpectrometryNon-significant differences between PD patients and controls.0
Squitti et al., 2007 [46]Graphite furnace atomic absorption.Non-significant differences between PD patients and controls.0
Gellein et al., 2008 [47]High Resolution Inductively Coupled Plasma Atomic Emission SpectrometryNon-significant differences between PD patients and controls.0
Bharucha et al., 2009 [48]Not specifiedSignificant decrease in PD patients compared to controls.2−
Nikam et al., 2009 [49] (plasma)Atomic absorption spectrophotometrySignificant decrease in PD patients compared to controls.2−
Fukushima et al., 2010, 2011, 2013, 2014 [50,51,52,53]Inductively Coupled Plasma Atomic Emission SpectrometryNon-significant differences between PD patients and controls.0
Arnal et al., 2010 [54] (plasma)Atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0
Henkin et al., 2010 [55]Atomic absorption spectrophotometryLack of a control group. Lack of a control group
Baillet et al., 2010 [56]Atomic absorption
Spectrophotometry		Non-significant differences between PD patients and controls.0
Ahmed & Santosh 2010 [57]Inductively Coupled Plasma Atomic Emission Spectrometry and atomic absorption spectroscopySignificant increase in PD patients compared to controls.2+
Ling & Bidhayasiri 2011 [58]Not specifiedNon-significant differences between PD patients and controls.0Data not given
McIntosh et al., 2012 [59] (plasma)Monochromatic X-ray fluorescence spectrometryNon-significant differences between PD patients and controls.0
Mariani et al.,2013 [60]Not specifiedNon-significant differences between PD patients and controls.0Data not available in the Supplementary Material.
Younes-Mehnni et al., 2013 [61]Plasma atomic absorption spectrophotometrySignificant decrease in PD patients compared to controls.2−
Zhao et al., 2013 [62] (plasma)Zeeman atomic absorption spectroscopy
with a graphite tube atomizer		Significant decrease in PD patients compared to controls.2−
Kumudini et al. 2014 [63] (plasma)Inductively Coupled Plasma Atomic Emission SpectrometrySignificant increase in PD patients compared to controls.2+
Meamar et al., 2016 [64] (plasma)Colorimetric methodLack of a control group. Lack of a control group.
Sanyal et al., 2016 [34]Atomic absorption spectrophotometry and flame atomic absorption spectrophotometrySignificant decrease in PD patients compared to controls.2−
Song et al., 2017 [65]ImmunoassayNon-significant differences between PD patients and controls.0
Gangania et al., 2017 [66]Colorimetric methodSignificant decrease in PD patients compared to controls.2−
Karpenko et al., 2018 [67] (plasma) Atomic absorption spectrophotometrySignificant decrease in PD patients compared to controls.3−
Ilyechova et al., 2018 [68]Graphite furnace atomic absorption spectrometrySignificant decrease in PD patients compared to controls.3−
Kim et al., 2018 [69]Inductively Coupled Plasma Atomic Emission SpectrometrySignificant decrease in PD patients compared to controls.1−
Ajsuvakova et al., 2020 [70]Inductively Coupled Plasma Atomic Emission SpectrometryNon-significant differences between PD patients and controls.
Fattah et al., 2020 [71]Graphite furnace atomic absorption spectrophotometrySignificant decrease in PD patients compared to controls.2−
Barmaki et al., 2021 [72]Graphite furnace atomic absorption spectrophotometrySignificant decrease in PD patients compared to controls.2−
Tripathi et al., 2021 [73]Spectrophotometery
immunoturbidimetry		Significant decrease in PD patients compared to controls.3−
Lee et al., 2023 [74]Inductively coupled plasma atomic emission spectrometryLack of a control group. Non-significant difference between PD patients with and without dementia. Lack of a control group.
Kim et al., 2023 [75]Inductively coupled plasma atomic emission spectrometryLack of a control group. Non-significant difference between PD patients with and without levodopa-induced dyskinesia. Lack of a control group.
Melek et al., 2023 [76]Atomic emission spectrometryNon-significant differences between PD patients and controls.0
Whole BloodBocca et al., 2006 [30]Inductively coupled plasma atomic emission spectrometrySignificant increase in PD patients compared to controls.2+
McIntosh et al., 2012 [59] Monochromatic X-ray fluorescence spectrometryNon-significant differences between PD patients and controls.0
Dušek et al., 2025 [37]Inductively coupled
plasma spectroscopy		Non-significant differences between PD patients and controls.0
UrineMcIntosh et al., 2012 [59] Monochromatic X-ray fluorescence spectrometryNon-significant differences between PD patients and controls.0
Forte et al., 2004 [28]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Bocca et al., 2006 [30]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0Data obtained as estimated from a graphic.
Fukushima et al., 2011, 2013, 2014 [51,52,53]Atomic absorption spectrometrySignificant increase in PD patients compared to controls.1+
Ajsuvakova et al., 2020 [70]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Shan et al., 2025 [77]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
HairForte et al., 2005 [78]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Bocca et al., 2006 [30]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls0Data obtained as estimated from a graphic.
Stefano et al., 2016 [79]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Ajsuvakova et al., 2020 [70]Inductively coupled plasma atomic emission spectrometrySignificant increase in PD patients compared to controls.2+
Ceruloplasmin
TissueAuthor, Year [Ref]MethodMain ResultsMain Results (2)Comments/
Observations
BrainLoeffler et al., 1996 [16]Enzyme-linked immunosorbent assay (ELISA)Significant increase in PD substantia nigra, frontal, temporal, and parietal cortices, and hippocampus; and non-significant differences with elderly controls in caudate, putamen, and cerebellum. 1+ in mentioned brain areasData given as corrected by proteins instead of g of tissue.
Loeffler et al., 2001 [80]Immunocytochemical staining with avidin-biotin-peroxidase complexNon-significant differences in ceruloplasmin immunoreactivity in substantia nigra, caudate, frontal and parietal cortices, parahippocampus, subiculum, and CA1 region. 0Data given in immunoreactivity for ceruloplasmins, not in concentrations, data not included.
CSFCampanella et al., 1973 [23]Colorimetric methodsNon-significant differences between PD patients and controls.0
Loeffler et al., 1994 [81]Enzyme-linked immunosorbent assay (ELISA)Non-significant differences between PD patients and controls.0
SerumCampanella et al., 1973 [23]Colorimetric methodsNon-significant differences between PD patients and controls.0
Jiménez-Jiménez et al., 1992 [40]Nephelometry immunoassayNon-significant differences between PD patients and controls.0
Molina-Arjona et al., 1999 [82]Nephelometry immunoassayNon-significant differences between PD patients and controls.0
Tórsdóttir et al., 1999 [42] (plasma)Nephelometry immunoassaySignificant decrease in PD patients compared to controls.0Non-significant changes when recalculated.
Tórsdóttir et al., 2006 [83]Nephelometry immunoassaySignificant decrease in PD patients compared to controls.0Non-significant changes when recalculated.
Squitti et al., 2007 [46]Immunoturbidimetric assayNon-significant differences between PD patients and controls.0
Bharucha et al., 2009 [48]Nephelometric immu-neturbidimetric assaySignificant decrease in PD patients compared to controls.2−
Nikam et al., 2009 [49] (plasma)Colorimetric methodSignificant decrease in PD patients compared to controls. Concentrations expressed as Units/L, Conversion to mg/dL not available. Data not included.
Arnal et al., 2010 [54] (plasma)Atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0
Jin et al., 2011 [84]Nephelometry immunoassaySignificant decrease in PD patients compared to controls.1−
Ling & Bidhayasiri 2011 [58]Immunoturbidimetric
assay with specific antiserum		Significant decrease in PD patients compared to controls.0Non-significant changes when recalculated.
Zhao et al. 2014 [85]Nephelometry immunoassaySignificant decrease in PD patients compared to controls.2−
Song et al., 2017 [65]ImmunoassaySignificant decrease in PD patients compared to controls.1−
Gangania et al., 2017 [66]Turbidimetric assayNon-significant differences between PD patients and controls.0
Karpenko et al., 2018 [67] (plasma)Atomic absorption spectrophotometrySignificant decrease in PD patients compared to controls.1−
Ilyechova et al., 2018 [68]Spectrophotometric method with p-phenylenediamineSignificant decrease in PD patients compared to controls.1−
Xu et al., 2018 [86]Immunoturbidimetric
assay		Non-significant differences between PD patients and controls.0
Si et al., 2018 [87] (plasma)Immunoturbidimetric assayNon-significant differences between PD patients and controls.0
Bakeberg et al., 2020 [88]Immunoturbidimetric assayLack of a control group. High impulsivity in PD patients with high compared with those with low ceruloplasmin levels. Lack of a control group.
Tripathi et al., 2021 [73]Spectrophotometery
immunoturbidimetry		Non-significant differences between PD patients and controls.0
Zinc
TissueAuthor, Year [Ref]MethodMain ResultsMain Results (2)Comments/
Observations
BrainRiederer et al., 1989 [12]Atomic absorption spectrophotometrySignificant increase in the raphe plus reticular formation in PD brains, and non-significant differences in other brain areas, including substantia nigra, caudate, putamen, and globus pallidus.0Data obtained as estimated from a graphic. Non-significant changes when recalculated.
Dexter et al., 1989 [13]Inductively coupled
plasma spectroscopy		Significant increase in substantia nigra from PD brains (50–54%) and in lateral putamen (18–35%). Non-significant differences between PD and controls in cerebellum, cerebral cortex, caudate nucleus, medial putamen, and globus pallidus.3+ for substantia nigra, 2+ for lateral putamenData obtained as estimated from a graphic.
Uitti et al., 1989 [14]Atomic emission spectroscopy and atomic absorption spectrophotometryNon-significant differences between PD and controls in the frontal cortex, caudate nucleus, and cerebellum.0
Hirsch et al., 1991 [89]X-ray microanalysisNon-significant differences between PD and controls in the substantia nigra (cells positive or negative for neuromelanin) and central grey substance. Data from the control group not available.
Dexter et al., 1991 [15]Inductively coupled
plasma spectroscopy		Significant increase in substantia nigra from PD brains. Non-significant differences between PD and controls in cerebellum, cerebral cortex (Brodmann
area 10), caudate nucleus, putamen, and globus pallidus.		0Non-significant changes when recalculated.
Mann et al., 1994 [90]Inductively coupled
plasma spectroscopy		Non-significant differences between PD patients and controls in the substantia nigra.0
Popescu et al., 2009 [91]Rapid-scanning X-ray fluorescence mappingDecrease fluorescence in substantia nigra, caudate, putamen, internal and external globus pallidus, inferior colliculus, white matter, internal capsule, grey matter, and optic tract.1− for all mentioned brain areas Data given in normalized fluorescence
Szczerbowska-Boruchoswska et al., 2012 [18]Synchrotron radiation-based X-ray fluorescence Significant increase in Zn mass fraction in the substantia nigra from PD patients.1+
Davies et al., 2014 [19]Particle-induced X-ray emission (PIXE) microscopyNon-significant differences between PD and controls in the substantia nigra, locus ceruleus, and occipital cortex.0
Gardner et al., 2017 [20]Inductively coupled
plasma spectroscopy		Non-significant differences between PD and controls in the olfactory bulb and olfactory tract.0
Genoud et al., 2017 [21]Inductively coupled
plasma spectroscopy		Non-significant differences between PD and controls in the substantia nigra, occipital cortex, and fusiform gyrus.0Full data not available
CSFMindadse & Tschikowani, 1967 [22]Not availableNot available Unable to get this article; abstract not available.
Jiménez-Jiménez et al., 1998 [26]Flame atomic absorption spectrophotometrySignificant decrease in PD patients.3−Controls were subjects with neurological diseases who had a clinical indication for lumbar puncture.
Forte et al., 2004 [28]Inductively coupled plasma atomic emission spectrometrySignificant decrease in PD patients.1−
Qureshi et al., 2006 [29]Atomic absorption
spectrophotometry with an electrothermal atomizer 		Non-significant differences between PD patients and controls.0
Bocca et al., 2006 [30]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0Data obtained as estimated from a graphic.
Alimonti et al., 2007 [31]Inductively Coupled Plasma Mass Spectrometry and Sector Field Inductively Coupled Plasma Mass SpectrometryNon-significant differences between PD patients and controls.0
Hozumi et al., 2011 [33]Inductively coupled
plasma spectroscopy		Significant increase in PD patients.3+
Sanyal et al., 2016 [34]Atomic absorption spectrophotometry and flame atomic absorption spectrophotometrySignificant decrease in PD patients compared to controls.1−
Maass et al., 2018 [35]Inductively
coupled plasma-sector field mass spectrometry		Non-significant differences between PD patients and controls.0
Willkommen et al., 2018 [36]Size-exclusion chromatography hyphenated to inductively coupled plasma mass spectrometry (SEC-ICP-MS)Non-significant differences between PD patients and controls.0
Dušek et al., 2025 [37]Inductively coupled
plasma spectroscopy		Non-significant differences between PD patients and controls.0
SerumMindadse & Tschikowani, 1967 [22]Not availableNot available Unable to get this article; abstract not available.
Jiménez-Jiménez et al., 1992 [40]Flame atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0
Abbott et al., 1992 [41] (plasma)Atomic absorption spectrophotometrySignificant decrease in PD patients.3−
Jiménez-Jiménez et al., 1998 [26]Flame atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0Controls were subjects with neurological diseases who had a clinical indication for lumbar puncture. PD patients and controls were not the same as in [40].
Kocatürk et al., 2000 [43] (plasma)Atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0
Forte et al., 2005 [78]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Hegde et al., 2004 [44]Inductively coupled plasma atomic emission spectrometrySignificant decrease in PD patients compared to controls.2−
Qureshi et al., 2006 [29]Atomic absorption
spectrophotometry with an electrothermal atomizer 		Non-significant differences between PD patients and controls.0
Bocca et al., 2006 [30]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0Data obtained as estimated from a graphic.
Alimonti et al., 2007 [31]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Squitti et al., 2007 [46]Graphite furnace atomic absorption.Non-significant differences between PD patients and controls.0
Gellein et al., 2008 [47]High resolution inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Nikam et al., 2009 [49]Atomic absorption spectrophotometrySignificant decrease in PD patients compared to controls.2−
Fukushima et al., 2010, 2011, 2013, 2014 [50,51,52,53]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Henkin et al., 2010 [55]Atomic absorption spectrophotometryLack of a control group. Lack of a control group.
Baillet et al., 2010 [56]Atomic absorption
spectrophotometry		Significant decrease in PD patients.0
Ahmed & Santosh 2010 [57]Inductively coupled plasma atomic emission spectrometry and atomic absorption spectroscopySignificant decrease in PD patients compared to controls.0
Brewer et al., 2010 [92]Atomic absorption spectrophotometrySignificant decrease in PD patients.1−
McIntosh et al., 2012 [59] (plasma)Monochromatic X-ray fluorescence spectrometryNon-significant differences between PD patients and controls.0
Younes-Mehnni et al., 2013 [61]Plasma atomic absorption spectrophotometrySignificant decrease in PD patients compared to controls.0Non-significant differences when recalculated.
Zhao et al., 2013 [62] (plasma)Fast sequential atomic absorption
spectroscopy		Significant decrease in PD patients compared to controls.2−
Verma et al., 2015 [93]Inductively coupled plasma atomic emission spectrometrySignificant decrease in PD patients.3−
Meamar et al., 2016 [64] (plasma)Colorimetric methodLack of a control group.
Sanyal et al., 2016 [34]Atomic absorption spectrophotometry and flame atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0
Kim et al., 2018 [69]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Ajsuvakova et al., 2020 [70]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Fattah et al., 2020 [71]Graphite furnace atomic absorption spectrophotometrySignificant decrease in PD patients compared to controls.2−
Barmaki et al., 2021 [72]Graphite furnace atomic absorption spectrophotometrySignificant decrease in PD patients compared to controls.2−
Matsuyama et al., 2021 [94]Not specifiedLack of a control group.
Lee et al., 2023 [74]Inductively coupled plasma atomic emission spectrometryLack of a control group. Increase in patients with PD who developed dementia compared to PD patients without dementia during the follow-up period. Lack of a control group.
Kim et al., 2023 [75]Inductively coupled plasma atomic emission spectrometryLack of a control group. Decrease in patients with PD who developed levodopa-induced dyskinesia compared to PD patients without this adverse effect during the follow-up period. Lack of a control group.
Melek et al., 2023 [76]Atomic emission spectrometrySignificant decrease in PD patients.2−
Whole BloodBocca et al., 2006 [30]Inductively coupled plasma atomic emission spectrometrySignificant increase in PD patients.1+
McIntosh et al., 2012 [59] Monochromatic X-ray fluorescence spectrometryNon-significant differences between PD patients and controls.0
Dušek et al., 2025 [37]Inductively coupled
plasma spectroscopy		Significant increase in PD patients.1+
UrineMcIntosh et al., 2012 [59] Monochromatic X-ray fluorescence spectrometryNon-significant differences between PD patients and controls.0
Forte et al., 2004 [28]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Bocca et al., 2006 [30]Inductively Coupled Plasma Atomic Emission SpectrometryNon-significant differences between PD patients and controls.0Data obtained as estimated from a graphic.
Brewer et al., 2010 [92]Atomic absorption spectrophotometrySignificant increase in PD patients.2+Standard deviation values not available. Not included in the meta-analysis.
Fukushima et al., 2011, 2013, 2024 [51,52,53]Atomic absorption spectrometryNon-significant differences between PD patients and controls.0
Ajsuvakova et al., 2020 [79]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Shan et al., 2025 [77]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
HairForte et al., 2004 [28]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Bocca et al., 2006 [30]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0Data obtained as estimated from a graphic.
Stefano et al., 2016 [79]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Dos Santos et al. 2018, 2019 [95,97]Flame atomic absorption spectrophotometrySignificant increase in PD patients.3+
Ajsuvakova et al., 2020 [70]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Manganese
TissueAuthor, Year [Ref]MethodMain ResultsMain Results (2)Comments/
Observations
BrainLarsen et al., 1981 [96]Neutron activation analysis with radiochemical separationNon-significant differences between PD patients (n = 2) and controls (n = 5) for 24 brain areas.0Not included in the meta-analysis. There are no statistical data.
Dexter et al., 1989 [13]Inductively coupled
plasma spectroscopy		Significant decrease in medial putamen from PD brains (20%). Non-significant differences between PD and controls in the substantia nigra, cerebellum, cerebral cortex, caudate nucleus, lateral putamen, and globus pallidus.1−Data obtained as estimated from a graphic.
Uitti et al., 1989 [14]Atomic emission spectroscopy and atomic absorption spectrophotometryNon-significant differences between PD and controls in the frontal cortex, caudate nucleus, and cerebellum.0
Dexter et al., 1991 [15]Inductively coupled
plasma spectroscopy		Non-significant differences between PD and controls in the substantia nigra, cerebellum, cerebral cortex (Brodmann
area 10), caudate nucleus, putamen, and globus pallidus. There was a 20% decrease in the medial putamen of PD.		0
Gardner et al., 2017 [20]Inductively coupled
plasma spectroscopy		Non-significant differences between PD and controls in the olfactory bulb and olfactory tract.0
Genoud et al., 2017 [21]Inductively coupled
plasma spectroscopy		Non-significant differences between PD and controls in the substantia nigra, occipital cortex, and fusiform gyrus.0Full data not available.
CSFMindadse & Tschikowani, 1967 [22]Not availableNot available Unable to get this article; abstract not available.
Pall et al., 1987 [24]Electrochemical atomization/atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0Controls were subjects with neurological diseases who had a clinical indication for lumbar puncture. Estimation from a graphic.
Gazzaniga et al., 1992 [25]Atomic absorption
spectrophotometry with electrothermal
atomization		Non-significant differences between PD patients and controls.0
Jiménez-Jiménez et al., 1998 [26]Flame atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0Controls were subjects with neurological diseases who had a clinical indication for lumbar puncture.
Forte et al., 2004 [28]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Bocca et al., 2006 [30]Sector field inductively coupled plasma mass spectrometryNon-significant differences between PD patients and controls.0
Hozumi et al., 2011 [33]Inductively coupled
plasma spectroscopy		Significant increase in PD patients.3+
Alimonti et al., 2007 [31]Inductively coupled plasma mass spectrometry and sector field inductively coupled plasma mass spectrometryNon-significant differences between PD patients and controls.0
Sanyal et al., 2016 [34]Atomic absorption spectrophotometry and flame atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0
Maass et al., 2018 [35]Inductively
coupled plasma-sector field mass spectrometry		Non-significant differences between PD patients and controls.0
Willkommen et al., 2018 [36]Size-exclusion chromatography hyphenated to inductively coupled plasma mass spectrometry (SEC-ICP-MS)Non-significant differences between PD patients and controls.0
Dušek et al., 2025 [37]Inductively coupled
plasma spectroscopy		Non-significant differences between PD patients and controls.0
SerumMindadse & Tschikowani, 1967 [22]Not availableNot available Unable to get this article; abstract not available
Kanabrocki et al., 1967 [38]RCL 512-Channel Analyzer (an instrument used in nuclear and radiation spectroscopy)Non-significant differences between PD patients and controls.0
Jiménez-Jiménez et al., 1992 [98]Flame atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0
Jiménez-Jiménez et al., 1998 [26]Flame atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0Controls were subjects with neurological diseases who had a clinical indication for lumbar puncture. PD patients and controls were not the same as in [CMZ-14].
Forte et al., 2004 [28]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Hegde et al., 2004 [44]Inductively coupled plasma atomic emission spectrometrySignificant increase in PD patients compared to controls.3+Mean ± SD for controls not given. Not included in the meta-analysis.
Bocca et al., 2006 [30]Sector field inductively coupled plasma mass spectrometryNon-significant differences between PD patients and controls.0
Alimonti et al., 2007 [45]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Gellein et al., 2008 [47]High resolution inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Ahmed & Santosh 2010 [57]Inductively coupled plasma atomic emission spectrometry and atomic absorption spectroscopySignificant increase in PD patients compared to controls.1+
Kumudini et al. 2014 [63] (plasma)Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Verma et al., 2016 [93]Inductively Coupled Plasma Atomic Emission SpectrometrySignificant increase in PD patients.2+
Sanyal et al., 2016 [34]Atomic absorption spectrophotometry and flame atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0
Ajsuvakova et al., 2020 [70]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Lee et al., 2023 [74]Inductively coupled plasma atomic emission spectrometryLack of a control group. Non-significant difference between PD patients with and without dementia. Lack of a control group.
Kim et al., 2023 [75]Inductively coupled plasma atomic emission spectrometryLack of a control group. Non-significant difference between PD patients with and without levodopa-induced dyskinesia. Lack of a control group.
Whole BloodBocca et al., 2006 [30]Sector field inductively coupled plasma mass spectrometryNon-significant differences between PD patients and controls.0Data obtained as estimated from a graphic.
Fukushima et al., 2010, 2011, 2013 [50,51,52]Atomic absorption spectrometrySignificant increase in PD patients.3+
Dušek et al., 2025 [37]Inductively coupled
plasma spectroscopy		Non-significant differences between PD patients and controls.0
UrineJiménez-Jiménez et al., 1992 [98]Flame atomic absorption spectrophotometryNon-significant differences between PD patients and controls.0
Forte et al., 2004 [28]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Bocca et al., 2006 [30]Sector field inductively coupled plasma mass spectrometrySignificant decrease in PD patients.2−
Fukushima et al., 2010, 2011, 2013 [50,51,52]Atomic absorption spectrometryNon-significant differences between PD patients and controls.0
Ajsuvakova et al., 2020 [70]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Shan et al., 2025 [77]Inductively coupled plasma atomic emission spectrometrySignificant increase in PD patients.3+
HairBocca et al., 2006 [30]Sector field inductively coupled plasma mass spectrometrySignificant increase in PD patients.3+
Stefano et al., 2016 [79]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Ajsuvakova et al., 2020 [70]Inductively coupled plasma atomic emission spectrometryNon-significant differences between PD patients and controls.0
Table 3. Comparison of techniques for measuring Cu, Zn, and Mn in biological tissues [117,118,119,120,121,122,123].
Table 3. Comparison of techniques for measuring Cu, Zn, and Mn in biological tissues [117,118,119,120,121,122,123].
TechniquePrincipleSensitivity for Cu, Zn, MnAdvantagesLimitations
Atomic Absorption Spectrophotometry (AAS)Absorption of element-specific radiation by free atomsModerateReliable, relatively low costSingle-element analysis
Flame Atomic Absorption Spectrophotometry (FAAS)AAS with flame atomizationModerate for Cu, Zn; low for MnSimple, rapid, inexpensiveInsufficient sensitivity for low Mn
Electrothermal Atomization/AAS (ETAAS)Electrical heating atomizationHigh High sensitivity, small sample volumeMatrix interferences
Graphite Furnace AAS (GFAAS)AAS using graphite furnaceVery highExcellent sensitivityLow throughput, single-element
Inductively Coupled Plasma Spectroscopy (ICP-OES)Optical emission from plasma-excited atomsHigh Multi-element capabilityHigher cost than AAS
ICP–Sector Field Mass Spectrometry (ICP-SFMS)Plasma ionization and high-resolution MSExtremely highOutstanding sensitivity/selectivityVery high cost, complex
Monochromatic X-ray Fluorescence (XRF)Characteristic X-ray emissionModerateNon-destructiveLimited sensitivity in soft tissues
ImmunoturbidimetryAntigen–antibody turbidity measurementIndirectAutomated, clinical useDoes not measure metals directly
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Jiménez-Jiménez, F.J.; Alonso-Navarro, H.; García-Martín, E.; Martín-Gómez, M.A.; Salgado-Cámara, P.; Cárcamo-Fonfría, A.; Arroyo-Solera, M.; Agúndez, J.A.G. Copper, Ceruloplasmin, Zinc, and Manganese Levels in Brain and Biological Fluids from Parkinson’s Disease Patients: Systematic Review and Meta-Analysis. Cells 2026, 15, 288. https://doi.org/10.3390/cells15030288

AMA Style

Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Martín-Gómez MA, Salgado-Cámara P, Cárcamo-Fonfría A, Arroyo-Solera M, Agúndez JAG. Copper, Ceruloplasmin, Zinc, and Manganese Levels in Brain and Biological Fluids from Parkinson’s Disease Patients: Systematic Review and Meta-Analysis. Cells. 2026; 15(3):288. https://doi.org/10.3390/cells15030288

Chicago/Turabian Style

Jiménez-Jiménez, Félix Javier, Hortensia Alonso-Navarro, Elena García-Martín, Miguel Angel Martín-Gómez, Paula Salgado-Cámara, Alba Cárcamo-Fonfría, Margarita Arroyo-Solera, and José A. G. Agúndez. 2026. "Copper, Ceruloplasmin, Zinc, and Manganese Levels in Brain and Biological Fluids from Parkinson’s Disease Patients: Systematic Review and Meta-Analysis" Cells 15, no. 3: 288. https://doi.org/10.3390/cells15030288

APA Style

Jiménez-Jiménez, F. J., Alonso-Navarro, H., García-Martín, E., Martín-Gómez, M. A., Salgado-Cámara, P., Cárcamo-Fonfría, A., Arroyo-Solera, M., & Agúndez, J. A. G. (2026). Copper, Ceruloplasmin, Zinc, and Manganese Levels in Brain and Biological Fluids from Parkinson’s Disease Patients: Systematic Review and Meta-Analysis. Cells, 15(3), 288. https://doi.org/10.3390/cells15030288

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop